

Rowan University

Rowan Digital Works

School of Osteopathic Medicine Faculty
Scholarship

School of Osteopathic Medicine

1-16-2018

Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression

Jan Jezek

Rowan University School of Osteopathic Medicine

Katrina Cooper

Rowan University School of Osteopathic Medicine

Randy Strich

Rowan University School of Osteopathic Medicine

Follow this and additional works at: https://rdw.rowan.edu/som_facpub



Part of the [Cancer Biology Commons](#), [Cell Biology Commons](#), and the [Molecular Biology Commons](#)

Recommended Citation

Ježek J, Cooper KF, Strich R. Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression. *Antioxidants*. 2018; 7(1):13. doi: 10.3390/antiox7010013. PMID: 29337889. PMCID: PMC5789323.

This Article is brought to you for free and open access by the School of Osteopathic Medicine at Rowan Digital Works. It has been accepted for inclusion in School of Osteopathic Medicine Faculty Scholarship by an authorized administrator of Rowan Digital Works.



Review

Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression

Jan Ježek , Katrina F. Cooper * and Randy Strich

Department of Molecular Biology, Rowan University Graduate School of Biomedical Sciences, Stratford, NJ 08084, USA; jezekj6@rowan.edu (J.J.); strichra@rowan.edu (R.S.)

* Correspondence: cooperka@rowan.edu

Received: 11 December 2017; Accepted: 9 January 2018; Published: 16 January 2018

Abstract: Mitochondria are organelles with a highly dynamic ultrastructure maintained by a delicate equilibrium between its fission and fusion rates. Understanding the factors influencing this balance is important as perturbations to mitochondrial dynamics can result in pathological states. As a terminal site of nutrient oxidation for the cell, mitochondrial powerhouses harness energy in the form of ATP in a process driven by the electron transport chain. Contemporaneously, electrons translocated within the electron transport chain undergo spontaneous side reactions with oxygen, giving rise to superoxide and a variety of other downstream reactive oxygen species (ROS). Mitochondrially-derived ROS can mediate redox signaling or, in excess, cause cell injury and even cell death. Recent evidence suggests that mitochondrial ultrastructure is tightly coupled to ROS generation depending on the physiological status of the cell. Yet, the mechanism by which changes in mitochondrial shape modulate mitochondrial function and redox homeostasis is less clear. Aberrant mitochondrial morphology may lead to enhanced ROS formation, which, in turn, may deteriorate mitochondrial health and further exacerbate oxidative stress in a self-perpetuating vicious cycle. Here, we review the latest findings on the intricate relationship between mitochondrial dynamics and ROS production, focusing mainly on its role in malignant disease.

Keywords: mitochondrial dynamics; mitochondrial ultrastructure; redox signaling; oxidative stress; reactive oxygen species; superoxide; cancer

1. Introduction

1.1. From Bean to Interconnected Web

In textbooks, mitochondria are classically depicted as round, bean-like organelles [1]. The oval shape of mitochondria observed by electron microscopy is consistent with the endosymbiotic theory that mitochondria evolved from a bacterial ancestor [2–4]. However, in living cells, mitochondria typically display dynamic networks of interconnected tubules with many branching points (Movie S1). The fluctuating nature of mitochondrial ultrastructure affords these organelles flexibility in regulating the bioenergetic flux of key molecular elements such as ATP, lipids, proteins, mitochondrial DNA (mtDNA), metabolites, cofactors, and ions throughout the entire mitochondrial network [5,6]. Small guanosine 5'-triphosphatase (GTPase) proteins like Miro help provide a high degree of homeostatic heterogeneity within the mitochondrial matrix by trafficking mitochondria along cytoskeletal filaments within [7,8] or between cells [9], thereby exposing mitochondria to distinct biochemical milieus [10]. Although mitochondrial motility was predominantly studied in neurons where mitochondria serve a specialized function [11], recent literature has revealed molecular players of the neuronal mitochondrial transport machinery that may be deregulated in cancers [12]. In this

scenario, these molecular motors hijack mitochondria and transfer them into cancer cell peripheries as a localized energy supply for increased mobility and metastasis of the tumor. Accordingly, mitochondrial fragmentation is believed to facilitate repositioning of mitochondria in cancer cells [13].

1.2. The Fission/Fusion Machinery

The overall steady-state morphological appearance of the mitochondrial reticulum is governed by the opposing activities of large GTPases directing either fission or fusion. Fusion of the outer and inner mitochondrial membrane (OMM and IMM) is mediated by mitofusins Mfn1 [14] or Mfn2 [15] and optic atrophy 1 (Opa1) [16,17], respectively. Profusion activity has also been reported for mitochondrial phospholipase D (PLD) [18] and mitofilin [19], which is part of the newly-discovered mitochondrial contact site and cristae organizing system (MICOS) [20,21]. In response to oxidative stress [22–24] or during cell division [25], the recruitment and activation of the mitochondrial fission GTPase, dynamin-related protein 1 (Drp1), shifts the balance toward the fragmented phenotype [26–28]. Oligomerization of Drp1 into a spiral-shaped filament around a mitochondrial tubule precedes the simultaneous constriction of both OMM and IMM, which occurs in a GTP-dependent manner [29]. Mitochondrial fission factor (Mff), mitochondrial fission 1 (Fis1), or mitochondrial dynamic proteins 49 and 51 (MiD49 and MiD51) are receptor-adapters that actively facilitate Drp1 interaction with the OMM during mitochondrial division [30–32]. Drp1 is post-translationally regulated via phosphorylation, ubiquitination, SUMOylation, and S-nitrosylation. For example, phosphorylation at Ser616 by the protein kinase C isoform δ (PKC δ) is activating, whereas phosphorylation at Ser637 by protein kinase A (PKA) inhibits Drp1 function [33]. Moreover, activity of the classic GTPase dynamin 2 (Dyn2) is required for final mitochondrial scission, indicating that this process is complex, requiring multiple steps and contributing factors [34].

1.3. Linking Mitochondrial Dynamics to Cell Death Pathways

Fragmentation of the mitochondrial network is linked with several physiological indicators of mitochondrial dysfunction, including loss of mitochondrial membrane potential ($\Delta\Psi_m$), decreased respiration and oxidative phosphorylation (OXPHOS), metabolic shift towards glycolysis, and increased mitochondrial ROS formation [33]. Glucose or fatty acid catabolism may also give rise to fragmented mitochondria, albeit with hyperpolarized $\Delta\Psi_m$ and augmented OXPHOS [35]. Collapse of the reticular form of mitochondria into fragments represents a key intermediate accompanying the activation of either salvaging or pro-death pathways depending on the stimulus. Resultant fragments of dysfunctional mitochondria can be selectively targeted for mitophagy to promote cell survival [36] or, in severe oxidative stress, trigger the intrinsic pathway of apoptosis (Figure 1) [37]. A common denominator for apoptotic and mitophagic stress response is the involvement of mitochondrial fission, perhaps triggered by mitochondrial ROS [38,39].

Intrinsic, or mitochondrial, apoptosis is characterized by increased association of the pro-apoptotic protein Bcl-2-associated X (Bax) with the OMM [40]. Bax, and its close homolog Bcl-2 homologous antagonist/killer (Bak), which constitutively resides in OMM, oligomerize to induce mitochondrial outer membrane permeabilization (MOMP). MOMP is accompanied by the release of pro-apoptotic factors, including cytochrome C, apoptosis-inducing factor (AIF), second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO), Omi/high temperature requirement protein A2 (Omi/HtrA2), and other second-messengers that initiate either caspase-dependent or caspase-independent cell death [41,42]. Although regulation of MOMP by mitochondrial dynamics is still elusive, considerable progress has been made towards visualizing Bax-mediated OMM pore formation in cells by means of super-resolution microscopy [43–45]. Consistent with a positive role for fission in programmed cell death (PCD), promoting fusion or inhibiting fragmentation prevents or delays the onset of apoptosis [46] or mitophagy [47]. Given that evading apoptosis is a hallmark of cancer, correct control of mitochondrial dynamics is critical for slowing or inhibiting tumor progression [22,36,48–50]. In addition, failure of

these mitochondrial quality control check-points can contribute to the development of degenerative pathologies such as type 2 diabetes [51–53], heart and brain ischemia-reperfusion (I/R) injury [54], cardiovascular disorders [55–59], and neuropathies [59–61] such as Parkinson’s [62] and Alzheimer’s disease [63]. Mitochondrial dysregulation is also thought to contribute to physiological processes associated with aging [64,65]. Are fragmented mitochondria a cause or consequence of ROS overproduction? Is it the severity of mitochondrial dysfunction that discriminates between redox signaling and oxidative stress? Can oxidative stress be regulated by mitochondrial morphology? Are there different mitochondrial fission phenotypes? Can we therapeutically treat mitochondrial dynamics? This review focuses on the interplay between mitochondrial dynamics and ROS homeostasis relevant to the etiology of malignant neoplastic diseases.




Figure 1. Changing cell fates depending on oxidative damage extent and mitochondrial dynamics. Under mild oxidative stress conditions (top), clearance of defective mitochondrion (yellow) by mitophagy reduces ROS levels and enhances cell survival. Acute oxidative stress (bottom) promotes extensive mitochondrial fission and dysfunction that ultimately leads to elevated ROS, loss of mitochondrial integrity (green) and apoptotic cell death.

2. Modulation of Mitochondrial Dynamics by Reactive Oxygen Species

2.1. Mitochondria Are a Prime Source of ROS

A primary function of mitochondria is to generate proton-motive force, required for ATP synthesis during OXPHOS to support cellular processes. As such, mitochondria constitute a major metabolic hub, or a “molecular furnace”, in which catabolic pathways intersect to oxidize nutrients. Along the electron transport chain (ETC), up to 2% of electrons leak before reaching Complex IV, incompletely reacting with oxygen in a one-electron reduction to produce superoxide (anion radical) instead of a water molecule [66]. Mitochondria are the major producer of superoxide and other downstream ROS in the cell [67], the main source of mitochondrially-derived superoxide being Complex I and III [68]. Additionally, mitochondrial superoxide is generated by electron-transferring flavoprotein-ubiquinone oxidoreductase during fatty acid oxidation, glycerol-3-phosphate dehydrogenase, and other IMM-associated oxidoreductases [69]. Superoxide is membrane-impermeant and is readily dismutated to non-radical, membrane-diffusible, H_2O_2 by superoxide dismutase (SOD) or non-enzymatic mechanisms [70,71]. As a membrane-diffusible species, mitochondrially-generated H_2O_2 has been implicated in cell-wide redox signal transduction [72–77]. H_2O_2 can be further reduced by divalent metal ions or superoxide in the Fenton [78] or Haber-Weiss reactions [79], respectively, to produce the hydroxyl radical ($\bullet OH$). This highly toxic molecule promiscuously reacts with a broad range of metabolites, thus inducing oxidative damage [80]. Depending on the physiological context, NADPH oxidases (NOX) and dual oxidases (DUOX) can further contribute to cellular superoxide formation [81].

2.2. Mitochondrial ROS and Cancer, a Double-Edged Sword

ROS are well known activators of apoptosis [82,83]. Due to oncogenic mutations, increased metabolic activity, or decreased mitochondrial function, many cancer types are intrinsically associated with elevated ROS generation [84–86] and mitochondrial fragmentation [33,87]. In addition to being a mutagenic motor that can drive a cell out of senescence, conventional anti-cancer strategies utilize pro-oxidant drugs to push the ROS levels beyond a death-inducing threshold specifically in cancer but not normal cells [88–91]. A typical example is cisplatin, which stimulates both nuclear DNA and mtDNA damage with concomitant mitochondrial fission [22] and increased mitochondrial ROS generation [92]. As proof of concept, antioxidants interfere with the therapeutic mechanism of cisplatin [93]. In addition to chemical pro-oxidants, singlet oxygen ($^1\text{O}_2$) itself is a ROS molecule that has gained particular attention in the treatment of shallow tumors such as skin melanoma by photodynamic therapy (PDT). In PDT, $^1\text{O}_2$ and free radicals are generated by irradiation of a pre-administered photosensitizing drug to induce apoptotic or necrotic cell death in cancer cells [94,95].

Dwelling in close proximity to the epicenter of oxidative metabolism, mtDNA is considered particularly vulnerable to free radicals and oxidative damage. The free radical theory of ageing is defined by the positive correlation between accumulated ROS and mtDNA mutations [96]. Considering that the mitochondrial genome encodes subunits of four out of five ETC Complexes (Complex I and III–V), mutations in mtDNA predispose ageing cells to mitochondrial dysfunction in a self-perpetuating vicious cycle [97]. Intramitochondrial mixing by coordinated mitochondrial fission and fusion cycles could represent an important complementary mechanism to preserve mtDNA integrity against oxidative injury [98]. Taken together, observations that ageing is associated with the fragmented mitochondrial phenotype and mtDNA damage would seem to suggest mitochondrial dynamics and ROS formation are mutually intertwined physiological processes that contribute to a slow decay of mitochondrial function during ageing.

2.3. Antioxidant Defense Systems

In order to cope with elevated ROS production, cells utilize a host of intricate antioxidant-defense mechanisms. The most abundant intracellular antioxidant, glutathione (GSH), participates in H_2O_2 detoxification through thiol-disulfide interchange catalyzed by glutathione peroxidase (GPX), yielding oxidized glutathione (GSSG) [99,100]. Glutathione reductase, in turn, plays a key role in maintaining the reduced form of glutathione [101]. In addition to its direct antioxidant capacity, GSSG contributes to antioxidant defense by inducing mitochondrial hyper-fusion in an Mfn1- and Mfn2-dependent manner [102]. Other H_2O_2 scavengers include catalase, which is mainly located in the peroxisomes where it converts H_2O_2 to water and oxygen [103], and the peroxiredoxin (PRX) system [104], relying upon the thioredoxin (TRX) and thioredoxin reductase catalytic cycle [105,106]. Stable peroxiredoxin 3 depletion in transformed mesothelioma cells leads to a hyper-fused mitochondrial phenotype, which is rescued by overexpression of mitochondrially-targeted or cytosolic catalase [107]. Additionally, antioxidant action is inherent in the activity of the uncoupling protein (UCP) family [108,109] and DJ-1 [110]. Ectopic overexpression of SET, an inhibitor of protein phosphatase 2A, in human embryonic kidney cancer cells increases UCP2 and UCP3 levels in parallel with Drp1- and Fis1-dependent mitochondrial fragmentation and diminished autophagic flux [111]. In the mouse model of I/R injury, DJ-1 elicits cardioprotection by preventing excessive mitochondrial fission [112]. Although antioxidant systems are recognized therapeutic targets, they are prone to transcriptional activation by oncogenes and thereby enhance tumorigenesis and chemoresistance [113,114].

3. Signaling Pathways Controlling Mitochondrial Dynamics

ROS-generating stimuli that induce mitochondrial network fragmentation can be divided into either external insults such as during treatment with pro-oxidants or chemotherapeutic agents, PDT, ionizing radiation, immune response, or viral infection that incur cell injury, or be part of physiological

redox signaling, for example during hypoxia. In general, stress response signaling pathways convey both external and internal cues between a redox-sensitive receptor and the downstream effectors of the mitochondrial fission machinery (Figure 2). How these signals regulate mitochondrial fission and converge upon the apoptotic stress response is still rather enigmatic and therefore an area of active research. This section will review the current trends and paradigms of ROS-mediated signaling that form a link between redox-sensing elements and mitochondrial dynamics and their role in cancer invasiveness, tumor progression, and metastasis.




Figure 2. Simplified relationship between ROS-induced redox signaling and mitochondrial dynamics. ROS stimuli are recognized by redox sensors (top), which transduce the signal to their respective effector kinases (center). Phosphorylation by these kinases can either inhibit mitochondrial fusion (red) or stimulate fission (green) proteins that results in the shift of the overall balance from elongated to fragmented morphology (bottom). As indicated, Ras/ERK MAPK signaling involves multiple kinases. Redox sensor for mammalian cyclin C pathway has not yet been determined.

3.1. Nrf2/Keap1 Signaling

The master regulator of cellular stress response is the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2), which reacts to exogenous stimuli by translocating from the cytosol to nucleus and initiating the expression of a broad range of antioxidant-defense and cytoprotective genes [115,116]. Since Nrf2 is upregulated in numerous tumors, it has been viewed as a promising target for cancer chemoprevention and therapy [117]. Kelch-like ECH-associated protein 1 (Keap1) is an E3 ubiquitin ligase and a redox-sensor for Nrf2 signaling that in the absence of oxidative stress targets Nrf2 for ubiquitin-mediated destruction [118]. Nrf2 is stabilized in the cytosol upon oxidative or electrophilic stress. Although Nrf2 was demonstrated to influence mitochondrial bioenergetics [119], the underlying mechanism is poorly understood. For example, mutant Huntingtin interferes with Nrf2 signaling, which resulted in increased fragmentation of mitochondrial network in response to low-level H_2O_2 treatment and increased susceptibility to oxidative stress in striatal cells [120]. Furthermore, Nrf2 mediates the redox-dependent effect of sulforaphane, an isothiocyanate found in cruciferous vegetables, on increased mitochondrial fragmentation, Bax induction, and the ensuing apoptosis in prostate cancer cells [121]. This response was specific to tumor cells as sulforaphane behaved as an antioxidant and promoted mitochondrial fusion and nephroprotection in parallel experiments using a

non-transformed kidney cell line. Altogether, these studies imply that activation of the Nrf2 antioxidant response can be a prospective therapeutic strategy in both neurodegenerative and malignant diseases.

3.2. HIF1 α -Mediated Response to Hypoxia

The classic example of redox sensing in cancer is the stabilization of the transcription factor hypoxia-inducible factor 1 α (HIF1 α) that allows solid tumors to adapt to low-oxygen stress by promoting aerobic glycolysis (Warburg's effect), angiogenesis, and tumor invasion [122,123]. Under normoxia, hydroxylation of HIF1 α by the prolyl hydroxylase domain (PHD) family of dioxygenases results in its binding to the von Hippel-Lindau protein followed by ubiquitin-dependent destruction [124]. HIF1 α is stabilized in the cytosol under hypoxia due to the limited availability of oxygen for the PHD-mediated hydroxylation step. Stabilized HIF1 α binds to the oxygen-insensitive subunit HIF1 β and the heterodimer subsequently translocates to the nucleus to initiate the transcription of a myriad of hypoxia-response genes to promote metabolic reprogramming stimulating aerobic glycolysis while suppressing OXPHOS activity [125]. HIF1 α induction stimulates expression of several glycolytic genes including phosphofructokinase, pyruvate kinase, and lactate dehydrogenase. Paradoxically, hypoxic exposure is accompanied by an initial oxidative burst of superoxide generated by mitochondria [126,127] or NOX enzymes [128]. The hypoxia-induced superoxide burst can originate from Complex I [129] or the outer Complex III ubiquinone-binding site [130]. Chandel hypothesized that the Complex III-derived superoxide signal, which is released into the mitochondrial intermembrane space, is necessary for PHD inactivation and consequent stabilization of HIF1 α at the onset of hypoxia. This model implicates mitochondria as active oxygen sensors [131].

There is a distinct association between oxygen deprivation and mitochondrial fragmentation in malignant cells. Hypoxia-induced Drp1 overexpression and mitochondrial fission have been linked to increased migration and metastatic activity in breast cancer MDA-MB-231 [132] and U251 glioblastoma cell lines [133]. Importantly, HIF1 α stabilization is required for hypoxia-induced mitochondrial fission [134]. Bioenergetic profiling identified an ovarian cell line (OVCA420) that exhibited fragmented mitochondria due to increased Drp1 expression [135]. These cells also displayed reduced respiration and increased glycolysis. In addition, OVCA420 cells failed to stabilize HIF1 α in a 1% oxygen environment reducing cellular fitness to hypoxic conditions. These findings are consistent with the model that mitochondrial dynamics not only play an important role in cellular energetics, but may also serve as a sensor for the hypoxic response. Taken together, these studies suggest that HIF1 α can act as a fundamental driver of both mitochondrial fission and cancer progression.

3.3. ASK1/p38 MAPK Pathway

The p38 mitogen-activated protein kinase (MAPK) is stimulated by the apoptosis signal-regulating kinase 1 (ASK1) protein kinase to transduce redox signals as well as other types of stress, to stimulate stress response programs, growth or differentiation depending on the signal [136,137]. Cytosolic thioredoxin 1 (Trx1) and mitochondrial thioredoxin 2 (Trx2) act as redox sensors for ASK1-mediated apoptosis signaling [138]. In their reduced form, TRXs sequester ASK1 from inducing stress- and cytokine-regulated apoptosis. This inhibition is relieved upon a pro-oxidant stimulus, which is sensed by intramolecular disulfide bond formation between Cys32 and Cys35 in TRX and this leads to the dissociation of the free kinase [139]. One role for the p38 MAPK signaling is in the adaptation of mitochondrial morphology to hypoxia. In response to hypoxia, p38 MAPK induces mitochondrial fragmentation by upregulating Siah2, which mediates derepression of Drp1 by the mitochondrial scaffolding protein AKAP121 [140]. Siah2 is an E3 ubiquitin ligase that targets AKAP121 for proteasomal degradation. In addition to p38 MAPK [141], Siah2 is upregulated by hypoxia-induced Akt signaling most likely through indirect mechanisms [142]. PKC δ -activated p38 MAPK was demonstrated to directly phosphorylate Drp1 to induce its mitochondrial translocation and subsequent mitochondrial fission in response to succinate challenge [143]. This change in mitochondrial network ultrastructure was required for promoting human mesenchymal stem cell

(hMSC) motility via upregulation and redistribution of F-actin. Moreover, pharmacological inhibition of p38 MAPK prevented mitochondrial fragmentation and the onset of mitophagy in a rat brain I/R (stroke) model [144]. In addition to p38 MAPK, c-Jun N-terminal kinase (JNK) can also be activated by ASK1 in response to oxidative stress [145]. JNK has mitochondrial substrates including those important for apoptosis [146] but a role in stress-induced fission/fusion has yet to be elucidated. These data indicate that p38-driven mitochondrial fission may represent an important cytological cue to promote tumorigenesis and metastasis.

3.4. Ras/ERK1/2 MAPK Pathway

The small GTPase Ras, is a well-known effector of the redox-mediated stress response [147] as well as a potent driver of malignant transformation when constitutively activated by mutation [148]. Collectively with three isoforms (Kras, Nras, and Hras), Ras is one of the most frequently mutated oncogenes occurring in approximately 25% of human tumors. When tethered to the plasma membrane through farnesyl and palmitoyl lipid moieties, Ras functions as a molecular switch oscillating between an active (GTP-bound) and inactive (GDP-bound) state. The GTP and GDP status of Ras is directed by the activity of guanine nucleotide exchange factors and GTPase-activating proteins, respectively [149,150]. Normally, Ras transduces external cues such as growth factor and cytokine stimulation to downstream MAPK cascade effectors composed of rapidly accelerated fibrosarcoma (Raf) (MAP3K), MAPK/extracellular signal-regulated kinase (MAPK/ERK) kinase 1 and 2 (MEK1/2) (MAP2K), and ERK1/2 (MAPK), to promote cell proliferation, differentiation, and motility [151]. In addition, Ras directly mediates redox signaling or initiates the oxidative stress response that can trigger apoptotic cell death [152]. Mechanistically, Ras senses ROS and RNS changes through its redox-sensitive cysteine found within a conserved consensus signature sequence NKXD, where X indicates redox-sensitive cysteine (not conserved). The reaction mechanism is thought to involve either one- or two-electron cysteine oxidation, the former being considered more common and proceeding through a thiyl radical intermediate RS^\bullet , where R denotes an alkyl group. RS^\bullet promotes oxidation of the bound guanine nucleotide resulting in its release and rapid turnover.

Numerous reports implicate Ras in modulating mitochondrial ultrastructure [153]. For example, Kashatus and Nascimento et al. reported that ERK2-mediated activating phosphorylation of Drp1 at Ser616 was required for mitochondrial fragmentation and tumor cell proliferation [154]. Similar effects of oncogenic Ras activation on the dynamics of mitochondria and tumor progression have been observed in cells and human melanoma cell lines [155]. In this setting, ERK1/2-dependent Drp1 activation promotes mitochondrial fission, $\Delta\Psi_m$ loss, and mitochondrial ROS generation during Ras^{G12V}-driven tumor transformation. This phosphorylation mark is also used by cyclin B-Cdk1 to simulate fission at mitosis to allow the efficient partitioning of mitochondria in daughter cells [156]. Overexpression of constitutively-active Hras^{G12V} mutant or MAPK activation was associated with increased mitochondrial fission and tumor growth in both in vitro human pancreatic cancer and mouse xenograft models. This fission may be stimulating cell division by generating enough ROS to serve as both a growth catalysis and mitochondrial segregation. Drp1 depletion by shRNA-mediated knockdown or expression of phosphorylation-defective mutant prevented mitochondrial fission and Ras-induced growth. Similarly, pharmacological inhibition of the MAPK pathway led to Drp1 downregulation, increased mitochondrial fusion, and metabolic activity. These findings suggest that mitochondrial dynamics could be a viable therapeutic strategy for Ras-driven neoplasia.

3.5. The Canonical NF- κ B Pathway

The redox-sensitive transcription factor nuclear factor κ B (NF- κ B) plays a major role in inflammation but is also commonly overexpressed and aberrantly activated in a variety of cancers. NF- κ B activation is associated with evasion of apoptosis and tumor inflammatory or immune responses [157,158]. NF- κ B is a common name for a dimeric complex formed by the members of the Rel family including p50, p52, RelA (p65), RelB and c-Rel [159]. NF- κ B normally resides in the

cytosol where it forms inhibitory complexes with members of the I κ B protein family (I κ B α , I κ B β , I κ B γ , I κ B ϵ , I κ B ζ , p100, p105, and Bcl-3) [160,161]. Upon activation by pro-inflammatory or redox stimuli, the I κ B kinase (IKK) complex composed of IKK α , IKK β , and NF- κ B essential modulator (NEMO) targets I κ B proteins for ubiquitin/proteasome-mediated degradation. This frees NF- κ B allowing nuclear translocation and the execution of inflammatory programs [162,163]. IKK α - and IKK $\alpha\beta$ -deficient mouse embryonic fibroblast (MEF) cells, but not those lacking IKK β , exhibit a fragmented mitochondrial network that positively correlate with reduced OPA1 expression [161]. In addition, both effects could be rescued by ectopic overexpression of IKK α . Curiously, PGC-1 α -dependent mitochondrial biogenesis and ROS production, as well as improved mitochondrial function and antioxidant capacity, were noted in peripheral blood mononuclear cells obtained from professional football players who underwent an eight week period of active training, all of which was attributed to NF- κ B activation [164].

Importantly, ROS-dependent NF- κ B activation was observed in parallel with increased mitochondrial Ca²⁺ levels and mitochondrial fission in immortalized mouse kidney epithelial cells and mouse splenocytes lacking the mitochondrial tumor suppressor Fus1 [165]. Accordingly, Fus1-deficient splenocytes exerted increased $\Delta\Psi_m$ and mitochondrial ROS production. Furthermore, NF- κ B and Nrf2 were implicated in cigarette smoke-induced mitochondrial fragmentation, dysfunction, and ROS generation in human airway smooth muscle (ASM) cells [166]. This was accompanied by increased Drp1 and decreased Mfn2 expression at both protein and mRNA level. In summary, these results highlight the central role of NF- κ B in regulating mitochondrial structure dynamics.

3.6. AMPK Redox Sensing

As an energy-sensing enzyme, AMP-activated protein kinase (AMPK) is the central gatekeeper of redox and bioenergetic homeostasis [167–169]. Upon nutrient deprivation, AMPK induces the activation of catabolic (glycolysis, amino acid and fatty acid oxidation) and inhibition of anabolic pathways (gluconeogenesis, fatty acid biosynthesis) to restore depleted ATP levels [170]. AMPK can be allosterically activated by an increased AMP:ATP ratio or directly by low glucose levels [171]. Structurally, AMPK is a heterotrimeric protein composed of catalytic α subunit as well as regulatory β and γ subunits, each of which has distinct isoforms (two isoforms exist for subunit α and β , three for γ) [172]. AMPK is frequently downregulated during tumorigenesis, which contributes to the Warburg phenotype, tumor adaptation, and cancer progression [173]. This is consistent with a tumor suppressor function for AMPK. However, AMPK activation has been observed in a subset of tumors, which may represent a survival mechanism for poorly vascularized tumors [174,175]. Apart from being a core energy-sensor, AMPK is also implicated in redox sensing. Indeed, the presence of H₂O₂ [176], superoxide [177], or reactive nitrogen species (RNS), such as NO [178], can stimulate AMPK. AMPK activity is induced by Trx1-dependent reduction of cysteine residues serving as a redox regulator [179]. An alternative hypothesis claims that oxidative stress stimulates AMPK activity indirectly by elevating the AMP:ATP ratio [180]. These mechanisms are not mutually exclusive and both may contribute to AMPK regulation depending on the context.

Mitochondrial ROS levels are kept in check by peroxisome proliferator-activated receptor-gamma coactivator-1 α (PGC-1 α)-dependent induction of antioxidant defense mechanisms [181]. AMPK stimulates PGC-1 α -dependent mitochondrial biogenesis [182], which may be important as fusion prevents mitochondrial dysfunction and ROS formation [183]. Conversely, AMPK mediates energy deprivation-induced mitochondrial fission following Complex I (rotenone) and III (antimycin A) inhibition by directly phosphorylating Mff [184]. This fragmented mitochondrial phenotype was observed following mitochondrial stress and is believed to predispose cells to mitophagy [185–187]. A recent study revealed a role for AMPK downstream of Drp1-mediated mitochondrial fission. Drp1 activity was augmented in brain tumor initiating (BTI) cells due to enhanced activating phosphorylation status leading to fragmented mitochondrial network morphology and increased cell survival [188]. Pharmacological inhibition or genetic knockdown of Drp1 was sufficient to induce

apoptosis, which was reversed in Drp1 and AMPK double-knockdown cells, implying a modulatory role of Drp1 on AMPK function. In another report, AMPK was stimulated by the concerted activity of the oncogene Myc and an OMM phospholipase PLD6 resulting in net mitochondrial fusion [189]. The indirect, myc-driven activation of AMPK led to the repression of the transcriptional regulators Yap and Taz, whose functions are associated with tumor resistance and metastasis, resulting in poor therapeutic outcome and patient survival [190,191]. Collectively, these investigations identify AMPK as another key player in integrating oncogenic transformation events to mitochondrial morphology changes during tumorigenesis. Moreover, manipulating mitochondrial dynamics can influence basic cancer metabolism, providing a new avenue to attack this disease.

3.7. Cyclin C Connects Oxidative Stress-Induced Fission to Apoptosis

Cyclin C is a highly conserved and ubiquitously expressed transcription factor that serves as a stress signaling effector that functions in the nucleus and at the mitochondria. Together with cyclin-dependent kinase 8 (Cdk8), cyclin C normally resides in the nucleus as part of the Mediator complex to regulate Cdk8 and polymerase II-dependent transcription. In the nucleus, cyclin C-Cdk8 function as co-activators with p53 to induce a subset of stress response genes [192]. Independent of transcription, cyclin C re-localizes to the mitochondria where it stimulates mitochondrial fission in response to oxidative stress in both mammalian [22] and yeast [23,24] models. In the cytoplasm, cyclin C directly activates Drp1 at OMM to facilitate mitochondrial fission. Intriguingly, oxidative stress-induced mitochondrial fragmentation did not require the Ser616 activating phosphorylation. This finding indicates that the cell recognizes stress-activated fission differently than that occurring during mitotic cell division. Furthermore, cyclin C is required for mitochondrial-dependent intrinsic, but not extrinsic, apoptosis [22]. This role for cyclin C at the mitochondria does not require Cdk8, suggesting that transcriptional regulation is not involved. In yeast cells, deletion of the mediator component *MED13* released cyclin C into the cytoplasm [193], revealing that cyclin C was necessary and sufficient to induce complete mitochondrial fragmentation. In stressed yeast cells, cyclin C release is facilitated by Med13 destruction mediated by the Skp, Cullin, F-box-containing complex (SCF) ubiquitin ligase and activating phosphorylation by the Slit2/Mpk1 MAPK [194]. Heterozygous deletion of cyclin C gene (*CCNC*) has been linked to the progression of acute lymphoblastic leukemia [195], osteosarcoma [196], and thyroid [197] cancer, suggesting that cyclin C is a bona fide tumor suppressor. Nevertheless, due to its utility, the cyclin C-mitochondrial axis is emerging as a prospective therapeutic target for both cancer and neurodegenerative diseases.

3.8. Other Redox Sensing Systems

Other redox signaling proteins including p53 [198], forkhead box O (FOXO) [199,200], Notch [201], PTEN [202], apurinic/aprimidinic endonuclease 1/redox factor 1 (APE1/Ref-1) [203], ataxia-telangiectasia mutated (ATM) [204], activator protein 1 (AP-1), cAMP response element binding protein (CREB), heat shock factor 1 (HSF1), and specificity protein 1 (SP1) [205,206] have also been tangentially associated with control of mitochondrial shape and structure. How mitochondrial dynamics control by these factors is coupled to their redox sensing function remains to be clarified.

4. Modulation of Reactive Oxygen Species by Mitochondrial Dynamics

An increasing body of evidence suggests a reciprocal link between mitochondrial morphology and ROS formation [207]. According to this hypothesis, mitochondrial shape and structure are intimately linked to the control of redox homeostasis by modulating ROS as a downstream signal (Figure 3). We will summarize recent observations of how mitochondrial fission and fusion influence mitochondrial ROS generation and how mitochondrial dynamics could be exploited as a potential therapeutic target for medical interventions.




Figure 3. Drivers of fission-induced mitochondrial ROS production. Mitochondrial network fragmentation can occur at both extremes of $\Delta\Psi_m$. Whereas low $\Delta\Psi_m$ values result from insults causing mitochondrial dysfunction (top), high $\Delta\Psi_m$ values can be achieved by metabolic stimulation such as with high glucose (bottom). Both stimuli result in fragmented organelles and subsequent generation of superoxide by ETC.

4.1. Mitochondrial-Derived ROS and Fission, the Vicious Cycle

Increased mitochondrial fragmentation corresponded to an unfavorable prognosis for hepatocellular carcinoma (HCC) patients presumably due to concurrent Drp1 upregulation and downregulation of Mfn1 [208]. The fragmented mitochondrial phenotype observed after Drp1 overexpression or Mfn1 knockdown in several HCC cell lines was associated with ROS overproduction, Akt (also known as protein kinase B) activation, evasion of apoptosis, and induction of general autophagy pathway [208]. Conversely, Drp1 knockdown or Mfn1 overexpression attenuated ROS generation. Mechanistically, mitochondrial fission-induced redox activation of Akt promoted Mdm2-dependent ubiquitin-proteasomal degradation of p53 and IKK-dependent NF- κ B activation [208]. Promisingly, mdivi-1, an allosteric and reversible Drp1 inhibitor, induced apoptosis and suppressed the growth of xenograft HCC tumors in immunodeficient mouse model [208]. Overexpression of Mff in human immortalized fibroblasts was reported to induce extensive mitochondrial fragmentation and concomitant mitochondrial dysfunction characterized by $\Delta\Psi_m$ loss, inefficient OXPHOS, and subsequent ATP depletion, giving rise to increased oxidative stress along with concomitant activation of mitophagy and NF- κ B-dependent autophagy [209]. Consequently, Mff-overexpressing fibroblasts exhibited metabolic reprogramming towards aerobic glycolysis and excessive lactate secretion, which supported the growth of breast cancer cells in a paracrine-like manner when co-injected into nude mice. Mitochondrial dynamics in cancer-associated stromal cells could therefore be an important driver of early tumorigenesis in neighboring cancer cells as well as an eventual therapeutic target. Recent work has shed more light on the role of NF- κ B-inducing kinase (NIK), a principal component of the non-canonical NF- κ B pathway, in controlling mitochondrial network dynamics and subcellular localization of mitochondria in relation to tumor malignancy and invasiveness [210]. Using loss- and gain-of-function approaches, Jung and Ravi et al. have shown that NIK relies on Drp1 to mediate mitochondrial fission. This was observed in MEF cells, several cancer cell lines, as well as patient glioblastoma tissue samples. NIK recruits Drp1 to OMM, facilitates its phosphorylation-dependent activation, and consequent mitochondrial fragmentation independently of IKK α , IKK β , and NF- κ B. Consistently, intracellular ROS levels were decreased in both NIK- or Drp1-deficient glioma BT25 cells. Apart from regulating mitochondrial shape, these authors also revealed the ability of NIK to promote mitochondrial migration and motility towards cell periphery and this coincided with increased tumor invasiveness.

Dynamic changes in mitochondrial network morphology were recognized to participate in the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) [211]. Mfn1- or

Mfn2-deficient MEF cells transduced with the pluripotency factor cocktail containing Oct4, Sox2, Klf4, and c-Myc (OSKM) displayed fragmented mitochondria and increased ROS formation [212]. Such redox stimulus induced HIF1 α stabilization even in the absence of hypoxia. In addition, Mfn1 or Mfn2 depletion in OSKM-treated MEF cells downregulated p53 and p21 and activated Ras and Raf. Altogether, this contributed to a genetic switch causing metabolic reprogramming from OXPHOS to glycolysis, which was identified in MEF-derived iPSCs. Analogically, mitochondrial dynamics has been implicated in the regulation of neural stem cell (NSC) maintenance and self-renewal [213]. Depletion of both Mfn1 and Mfn2 or Opa1 increased mitochondrial fragmentation and superoxide production without causing oxidative damage, consistent with the signaling role of mitochondrial fission-induced ROS. When assessed by a neurosphere formation assay, Opa1-deficient NSCs displayed compromised self-renewal capacity, which was reversed by antioxidant treatments. Conversely, Drp1-deficient NSCs showed opposite effects. In addition, employing rotenone or genetic deletion of AIF to specifically induce Complex I-mediated superoxide generation phenocopied the effect of Opa1 loss on neurosphere formation. Further supporting the role of mitochondrial dynamics in determining the fate of NSCs, mitochondrial morphology-regulated redox signaling was necessary for the execution of Nrf2-dependent developmental program responsible for the differentiation of NSCs into neurons.

4.2. Metabolic Stimulation

The outcome that metabolic changes have on mitochondrial function and dynamic responses can be different than those observed following genetic mutation. For example, in a cardiovascular injury model, hyperglycemic conditions trigger Drp1-mediated mitochondrial fragmentation and concomitant ROS formation that resulted in mitochondrial permeability transition (MPT)-dependent apoptosis [214]. This was observed in both rat heart myoblast H9c2 cell line and primary neonatal cardiomyocytes. In H9c2 cells, mitochondrial fission induced by high glucose levels (20 mM) stems from elevated mitochondrial metabolism and therefore cannot be associated with defective mitochondrial function [215]. In analogy, succinate induced Drp1-dependent mitochondrial fission in hMSC that stimulated ROS generation at high $\Delta\Psi_m$ and OXPHOS activity [143]. These results indicate that sufficient ROS can be generated by accelerated metabolism to push the cell past the cell death threshold. An interesting study found that in a model of diabetic nephropathy (DN), exposure of kidney glomerular mesangial cells to high glucose levels leads to mitochondrial translocation of Drp1, and subsequent mitochondrial fragmentation, increased ROS production, lipid peroxidation, p38 MAPK activation, and collagen IV synthesis [216]. Mdivi-1 abolished these effects including the translocation of Drp1 to mitochondria. Moreover, treatment with the antioxidant *N*-acetyl-L-cysteine (NAC) attenuated p38 MAPK phosphorylation, suggesting that Drp1-induced ROS activate p38 MAPK in a feed-forward regulatory loop. Inquiries into the spatial behavior of mitochondria during metabolic overload and/or reprogramming deserve further scientific attention not only in cancer but also in other metabolic disorders such as type 2 diabetes.

4.3. Inflammatory Stimulation

Exposure of mouse embryonic endothelial (MEE) or COS-7 cells to transforming growth factor beta (TGF β) led to increased mitochondrial fragmentation, which positively correlated with mitochondrial superoxide overproduction [217]. Treatment with the TGF β receptor I (T β RI) kinase inhibitor SB431542 reversed both effects in control MEE cells but not upon knockdown of the T β RI kinase substrate Smad2. Indeed, the authors went on to show that Smad2 promotes mitochondrial fusion by directly interacting with Mfn2 and recruiting the Rab and Ras interactor 1 (RIN1) as the guanine nucleotide exchange factor for Mfn2. Furthermore, an elegant study investigated the molecular underpinnings of osteogenic dysfunction during TNF α -induced inflammation [218]. TNF α treatment led to increased mitochondrial ROS formation and Drp1 expression followed by excessive mitochondrial fragmentation. Strikingly, both symptoms of mitochondrial dysfunction were inhibited by NAC or mdivi-1 treatment, thus further supporting the notion that superoxide generation and Drp1-mediated fission are intimately interlinked

phenomena. Furthermore, T cell activation by cluster of differentiation 3 (CD3) antibodies has been reported to induce mitochondrial fission and ROS production in a Drp1-dependent manner [219]. The activation of Drp1 proceeded through T cell receptor (TCR)-dependent NO signaling and resulted in production of interleukin 2 (IL-2) and the CD95 via ROS-activated NF- κ B. Increased levels of IL-2 and CD95 led to simultaneously augmented rates of proliferation and extrinsic apoptosis in CD3-activated T cells.

Lipopolysaccharide (LPS), a surface glycolipid of Gram-negative bacteria and an inflammatory endotoxin, has been found to stimulate mitochondrial fission, mitochondria- and NOX-derived superoxide production in immortalized microglial cell line [220]. As a regulated event, the observed ROS formation occurred downstream of the change in mitochondrial morphology since the effects were abolished by treatment with the antioxidant oleuropein, a secoiridoid glycoside abundant in olive leaf, which inhibited Drp1 Ser637 dephosphorylation as well as LPS-induced inflammation. To summarize, mitochondrial dynamics is an essential component for the inflammatory response that directs proliferation or cell death depending on the immune signal.

4.4. Anticancer Drugs

In addition to endogenous metabolites and compounds, several chemotherapeutic agents are proposed to generate ROS through altered mitochondrial morphology. Inhibitor of the hedgehog signaling pathway, cyclopamine tartrate, elicited antiproliferative and pro-apoptotic behavior in non-small-cell lung cancer cell lines by inducing mitochondrial fission accompanied by decreased respiration, increased $\Delta\Psi_m$, and ROS formation [221]. Cambogin, a naturally-occurring polycyclic polyprenylated acylphloroglucinol, displayed cytostatic and apoptosis-inducing effects in breast cancer cell lines. Increased mitochondrial superoxide as well as cytosolic NADPH oxidase 1 (Nox1)-mediated ROS generation paralleled elevated mitochondrial fission and diminished $\Delta\Psi_m$ following cambogin treatment [222]. The mechanism of action of cambogin may involve the release of ASK1 from inhibition by Trx1. Activated ASK1 is then free to stimulate apoptosis via JNK signaling. Nox1 inhibition or siRNA-mediated knockdown restored normal mitochondrial morphology and ROS production to basal values. The authors concluded that mitochondrial ROS may converge upon mitochondrial dynamics downstream of Nox1 activation. This interpretation is again consistent with the feed-forward regulatory mechanism of mitochondrial ROS-induced ROS generation during structural remodeling of mitochondria. Moreover, silica nanoparticles were reported to induce mitochondrial fragmentation in human umbilical vein endothelial cells, which was caused by dysregulation of the fission machinery proteins, $\Delta\Psi_m$ loss, and accompanied by increased mitochondrial ROS formation and decreased mtDNA copy number [223]. These studies underscore the fact that mitochondrial ultrastructure changes can be inherently part of the mechanism of action of ROS-generating chemotherapeutics.

4.5. Ionizing Radiation

Ionizing radiation composed of α particles (${}^4_2\text{He}^{2+}$) has been documented to upregulate Drp1 expression, induce mitochondrial fission, and cause damage to Complex II and IV in immortalized human small airway epithelial (SAE) cells [224]. Elevated levels of mitochondrial superoxide were one of the characteristics associated with α particle radiation-induced mitochondrial dysfunction. Whereas mdivi-1 pretreatment preserved the integrity of mitochondrial network after exposure of SAE cells to α radiation, it did not immediately rescue mitochondrial function implying that α particles cause direct damage to ETC components.

4.6. Viral Infection

Simultaneously increased ROS and mitochondrial fragmentation due to perturbed mitochondrial function were observed during the infection of astrocytoma U-87MG (glioma) cells by the vaccine strain of Venezuelan equine encephalitis virus (VEEV) [225]. Mdivi-1 treatment prevented VEEV-induced

mitochondrial fission and doxorubicin-induced apoptosis in U-87MG cells. Although the exact mechanism of VEEV infection is unknown, these data confirm that viruses are capable of impacting on the fission/fusion machinery to predispose infected cells towards cell death.

4.7. Cigarette Smoke

Cigarette smoke can be regarded as oxidative insult [226]. Cigarette smoke-induced mitochondrial ROS production that was observed in ASM cells [166] was prevented by Drp1 siRNA-mediated knockdown. Conversely, Mfn2 knockdown elevated mitochondrial ROS levels in the presence or absence of cigarette smoke. These results further support the role of mitochondrial dynamics in modulating mitochondria-generated ROS.

5. Conclusions

Mitochondrial network dynamics has important consequences for physiological homeostasis as well as in disease states. A vital determinant of mitochondrial structure is the mitochondrial membrane potential. Within physiological values of $\Delta\Psi_m$, mitochondria are interconnected and elongated. However, at both low (mitochondrial dysfunction) and high (metabolic saturation) extremes of $\Delta\Psi_m$, mitochondria display a fragmented phenotype accompanied by increased ROS generation. Given that mitochondrial fission represents an early step in apoptosis, mitochondrial ROS play a fundamental role at the intersection between these two processes. Although visually similar in appearance, two types of fragmented state should be distinguished—reversible and irreversible. Whether fragmentation of mitochondrial network commits cells to cell death is likely to be indicated by the presence of the latter phenotype. Structurally, this may be the terminal state of ROS-induced ROS vicious cycle that may involve escalating mitochondrial fission as a core component of this mechanism (Figure 4) [227]. Hence, manipulating mitochondrial morphology towards fission by pro-oxidants or towards fusion by antioxidants or mdivi-1 seems to be a viable therapeutic strategy in combating cancer and degenerative diseases, respectively [228].




Figure 4. The vicious cycle of mitochondrial fragmentation and ROS production. Fission of the mitochondrial network, such as during oxidative stress (Figure 2), induces mitochondrial ROS generation (Figure 3) initiating a self-perpetuating cycle promoting mitochondrial dysfunction, cell cycle progression and genetic mutation that stimulates neoplastic growth and tumor initiation.

Supplementary Materials: The following are available online at www.mdpi.com/2076-3921/7/1/13/s1. Movie S1: Movie illustrates 4-D imaging of mitochondrial network dynamics in living human hepatoma HepG2 cells permanently expressing mitochondrially-targeted GFP using a Zeiss confocal microscope. The temporal axis

does not correspond to a real time sequence due to the extended acquisition time required to capture each image in high resolution.

Acknowledgments: The authors acknowledge Zachary A. C. Kiss for help with the manuscript. This work was supported by NIH grant GM R15-113196 and GM RO1-113052 awarded to Katrina F. Cooper and Randy Strich, respectively.

Author Contributions: Jan Ježek wrote the manuscript and drew the figures. Randy Strich and Katrina F. Cooper edited the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nicholls, D.G.; Ferguson, S.J. *Bioenergetics*, 4th ed.; Academic Press, Elsevier: Amsterdam, The Netherlands, 2013; 419p.
2. Rongvaux, A. Innate immunity and tolerance toward mitochondria. *Mitochondrion* **2017**. [[CrossRef](#)] [[PubMed](#)]
3. Munoz-Gomez, S.A.; Wideman, J.G.; Roger, A.J.; Slamovits, C.H. The origin of mitochondrial cristae from alphaproteobacteria. *Mol. Biol. Evol.* **2017**, *34*, 943–956. [[CrossRef](#)] [[PubMed](#)]
4. Zorov, D.B.; Plotnikov, E.Y.; Silachev, D.N.; Zorova, L.D.; Pevzner, I.B.; Zorov, S.D.; Babenko, V.A.; Jankauskas, S.S.; Popkov, V.A.; Savina, P.S. Microbiota and mitobiota. Putting an equal sign between mitochondria and bacteria. *Biochemistry* **2014**, *79*, 1017–1031. [[CrossRef](#)] [[PubMed](#)]
5. Willems, P.H.; Rossignol, R.; Dieteren, C.E.; Murphy, M.P.; Koopman, W.J. Redox homeostasis and mitochondrial dynamics. *Cell Metab.* **2015**, *22*, 207–218. [[CrossRef](#)] [[PubMed](#)]
6. Mishra, P.; Chan, D.C. Metabolic regulation of mitochondrial dynamics. *J. Cell Biol.* **2016**, *212*, 379–387. [[CrossRef](#)] [[PubMed](#)]
7. Melkov, A.; Abdu, U. Regulation of long-distance transport of mitochondria along microtubules. *Cell. Mol. Life Sci.* **2017**. [[CrossRef](#)] [[PubMed](#)]
8. Wu, M.; Kalyanasundaram, A.; Zhu, J. Structural and biomechanical basis of mitochondrial movement in eukaryotic cells. *Int. J. Nanomed.* **2013**, *8*, 4033–4042. [[CrossRef](#)]
9. Berridge, M.V.; Neuzil, J. The mobility of mitochondria: Intercellular trafficking in health and disease. *Clin. Exp. Pharmacol. Physiol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
10. Tang, B.L. MIRO GTPases in mitochondrial transport, homeostasis and pathology. *Cells* **2016**, *5*, 1. [[CrossRef](#)] [[PubMed](#)]
11. Harbauer, A.B. Mitochondrial health maintenance in axons. *Biochem. Soc. Trans.* **2017**, *45*, 1045–1052. [[CrossRef](#)] [[PubMed](#)]
12. Altieri, D.C. Mitochondria on the move: Emerging paradigms of organelle trafficking in tumour plasticity and metastasis. *Br. J. Cancer* **2017**, *117*, 301–305. [[CrossRef](#)] [[PubMed](#)]
13. Pendin, D.; Filadi, R.; Pizzo, P. The concerted action of mitochondrial dynamics and positioning: New characters in cancer onset and progression. *Front. Oncol.* **2017**, *7*, 102. [[CrossRef](#)] [[PubMed](#)]
14. Cao, Y.L.; Meng, S.; Chen, Y.; Feng, J.X.; Gu, D.D.; Yu, B.; Li, Y.J.; Yang, J.Y.; Liao, S.; Chan, D.C.; et al. Mfn1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion. *Nature* **2017**, *542*, 372–376. [[CrossRef](#)] [[PubMed](#)]
15. Schrepfer, E.; Scorrano, L. Mitofusins, from mitochondria to metabolism. *Mol. Cell.* **2016**, *61*, 683–694. [[CrossRef](#)] [[PubMed](#)]
16. Pagliuso, A.; Cossart, P.; Stavru, F. The ever-growing complexity of the mitochondrial fission machinery. *Cell. Mol. Life Sci.* **2017**. [[CrossRef](#)] [[PubMed](#)]
17. MacVicar, T.; Langer, T. Opa1 processing in cell death and disease—The long and short of it. *J. Cell Sci.* **2016**, *129*, 2297–2306. [[CrossRef](#)] [[PubMed](#)]
18. Adachi, Y.; Itoh, K.; Yamada, T.; Cervený, K.L.; Suzuki, T.L.; Macdonald, P.; Frohman, M.A.; Ramachandran, R.; Iijima, M.; Sesaki, H. Coincident phosphatidic acid interaction restrains Drp1 in mitochondrial division. *Mol. Cell* **2016**, *63*, 1034–1043. [[CrossRef](#)] [[PubMed](#)]
19. Van Laar, V.S.; Berman, S.B.; Hastings, T.G. Mic60/mitofilin overexpression alters mitochondrial dynamics and attenuates vulnerability of dopaminergic cells to dopamine and rotenone. *Neurobiol. Dis.* **2016**, *91*, 247–261. [[CrossRef](#)] [[PubMed](#)]

20. Schorr, S.; van der Laan, M. Integrative functions of the mitochondrial contact site and cristae organizing system. *Semin. Cell Dev. Biol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
21. Wollweber, F.; von der Malsburg, K.; van der Laan, M. Mitochondrial contact site and cristae organizing system: A central player in membrane shaping and crosstalk. *Biochim. Biophys. Acta* **2017**, *1864*, 1481–1489. [[CrossRef](#)] [[PubMed](#)]
22. Wang, K.; Yan, R.; Cooper, K.F.; Strich, R. Cyclin C mediates stress-induced mitochondrial fission and apoptosis. *Mol. Biol. Cell* **2015**, *26*, 1030–1043. [[CrossRef](#)] [[PubMed](#)]
23. Strich, R.; Cooper, K.F. The dual role of cyclin C connects stress regulated gene expression to mitochondrial dynamics. *Microb. Cell* **2014**, *1*, 318–324. [[CrossRef](#)] [[PubMed](#)]
24. Cooper, K.F.; Khakhina, S.; Kim, S.K.; Strich, R. Stress-induced nuclear-to-cytoplasmic translocation of cyclin C promotes mitochondrial fission in yeast. *Dev. Cell* **2014**, *28*, 161–173. [[CrossRef](#)] [[PubMed](#)]
25. Horbay, R.; Bilyy, R. Mitochondrial dynamics during cell cycling. *Apoptosis* **2016**, *21*, 1327–1335. [[CrossRef](#)] [[PubMed](#)]
26. Ramachandran, R. Mitochondrial dynamics: The dynamin superfamily and execution by collusion. *Semin. Cell Dev. Biol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
27. Hu, C.; Huang, Y.; Li, L. Drp1-dependent mitochondrial fission plays critical roles in physiological and pathological progresses in mammals. *Int. J. Mol. Sci.* **2017**, *18*, 144. [[CrossRef](#)] [[PubMed](#)]
28. Antonny, B.; Burd, C.; De Camilli, P.; Chen, E.; Daumke, O.; Faelber, K.; Ford, M.; Frolov, V.A.; Frost, A.; Hinshaw, J.E.; et al. Membrane fission by dynamin: What we know and what we need to know. *EMBO J.* **2016**, *35*, 2270–2284. [[CrossRef](#)] [[PubMed](#)]
29. Kraus, F.; Ryan, M.T. The constriction and scission machineries involved in mitochondrial fission. *J. Cell Sci.* **2017**, *130*, 2953–2960. [[CrossRef](#)] [[PubMed](#)]
30. Atkins, K.; Dasgupta, A.; Chen, K.H.; Mewburn, J.; Archer, S.L. The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fission: Implications for human disease. *Clin. Sci.* **2016**, *130*, 1861–1874. [[CrossRef](#)] [[PubMed](#)]
31. Osellame, L.D.; Singh, A.P.; Stroud, D.A.; Palmer, C.S.; Stojanovski, D.; Ramachandran, R.; Ryan, M.T. Cooperative and independent roles of the Drp1 adaptors Mff, MiD49 and MiD51 in mitochondrial fission. *J. Cell Sci.* **2016**, *129*, 2170–2181. [[CrossRef](#)] [[PubMed](#)]
32. Liu, R.; Chan, D.C. The mitochondrial fission receptor Mff selectively recruits oligomerized Drp1. *Mol. Biol. Cell* **2015**, *26*, 4466–4477. [[CrossRef](#)] [[PubMed](#)]
33. Nagdas, S.; Kashatus, D.F. The interplay between oncogenic signaling networks and mitochondrial dynamics. *Antioxidants* **2017**, *6*, 33. [[CrossRef](#)]
34. Lee, J.E.; Westrate, L.M.; Wu, H.; Page, C.; Voeltz, G.K. Multiple dynamin family members collaborate to drive mitochondrial division. *Nature* **2016**, *540*, 139–143. [[CrossRef](#)] [[PubMed](#)]
35. Liesa, M.; Shirihai, O.S. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. *Cell Metab.* **2013**, *17*, 491–506. [[CrossRef](#)] [[PubMed](#)]
36. Bordi, M.; Nazio, F.; Campello, S. The close interconnection between mitochondrial dynamics and mitophagy in cancer. *Front. Oncol.* **2017**, *7*, 81. [[CrossRef](#)] [[PubMed](#)]
37. Martinez-Carreres, L.; Nasrallah, A.; Fajas, L. Cancer: Linking powerhouses to suicidal bags. *Front. Oncol.* **2017**, *7*, 204. [[CrossRef](#)] [[PubMed](#)]
38. Ciccarese, F.; Ciminale, V. Escaping death: Mitochondrial redox homeostasis in cancer cells. *Front. Oncol.* **2017**, *7*, 117. [[CrossRef](#)] [[PubMed](#)]
39. Wang, Y.; Nartiss, Y.; Steipe, B.; McQuibban, G.A.; Kim, P.K. ROS-induced mitochondrial depolarization initiates park2/parkin-dependent mitochondrial degradation by autophagy. *Autophagy* **2012**, *8*, 1462–1476. [[CrossRef](#)] [[PubMed](#)]
40. Pena-Blanco, A.; Garcia-Saez, A.J. Bax, Bak and beyond-mitochondrial performance in apoptosis. *FEBS J.* **2017**. [[CrossRef](#)] [[PubMed](#)]
41. Kim, H.J.; Maiti, P.; Barrientos, A. Mitochondrial ribosomes in cancer. *Semin. Cancer Biol.* **2017**, *47*, 67–81. [[CrossRef](#)] [[PubMed](#)]
42. Rathore, R.; McCallum, J.E.; Varghese, E.; Florea, A.M.; Busselberg, D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). *Apoptosis* **2017**, *22*, 898–919. [[CrossRef](#)] [[PubMed](#)]

43. Sahl, S.J.; Hell, S.W.; Jakobs, S. Fluorescence nanoscopy in cell biology. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 685–701. [[CrossRef](#)] [[PubMed](#)]
44. Grosse, L.; Wurm, C.A.; Bruser, C.; Neumann, D.; Jans, D.C.; Jakobs, S. Bax assembles into large ring-like structures remodeling the mitochondrial outer membrane in apoptosis. *EMBO J.* **2016**, *35*, 402–413. [[CrossRef](#)] [[PubMed](#)]
45. Salvador-Gallego, R.; Mund, M.; Cosentino, K.; Schneider, J.; Unsay, J.; Schraermeyer, U.; Engelhardt, J.; Ries, J.; Garcia-Saez, A.J. Bax assembly into rings and arcs in apoptotic mitochondria is linked to membrane pores. *EMBO J.* **2016**, *35*, 389–401. [[CrossRef](#)] [[PubMed](#)]
46. Kalkavan, H.; Green, D.R. MOMP, cell suicide as a BCL-2 family business. *Cell Death Differ.* **2018**, *25*, 46–55. [[CrossRef](#)] [[PubMed](#)]
47. Suarez-Rivero, J.M.; Villanueva-Paz, M.; de la Cruz-Ojeda, P.; de la Mata, M.; Cotan, D.; Oropesa-Avila, M.; de Laveria, I.; Alvarez-Cordoba, M.; Luzon-Hidalgo, R.; Sanchez-Alcazar, J.A. Mitochondrial dynamics in mitochondrial diseases. *Diseases* **2016**, *5*, 1. [[CrossRef](#)] [[PubMed](#)]
48. Simula, L.; Nazio, F.; Campello, S. The mitochondrial dynamics in cancer and immune-surveillance. *Semin. Cancer Biol.* **2017**, *47*, 29–42. [[CrossRef](#)] [[PubMed](#)]
49. Srinivasan, S.; Guha, M.; Kashina, A.; Avadhani, N.G. Mitochondrial dysfunction and mitochondrial dynamics—the cancer connection. *Biochim. Biophys. Acta* **2017**, *1858*, 602–614. [[CrossRef](#)] [[PubMed](#)]
50. Trotta, A.P.; Chipuk, J.E. Mitochondrial dynamics as regulators of cancer biology. *Cell. Mol. Life Sci.* **2017**, *74*, 1999–2017. [[CrossRef](#)] [[PubMed](#)]
51. Gonzalez-Franquesa, A.; Patti, M.E. Insulin resistance and mitochondrial dysfunction. *Adv. Exp. Med. Biol.* **2017**, *982*, 465–520. [[CrossRef](#)] [[PubMed](#)]
52. Rovira-Llopis, S.; Banuls, C.; Diaz-Morales, N.; Hernandez-Mijares, A.; Rocha, M.; Victor, V.M. Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications. *Redox Biol.* **2017**, *11*, 637–645. [[CrossRef](#)] [[PubMed](#)]
53. Wada, J.; Nakatsuka, A. Mitochondrial dynamics and mitochondrial dysfunction in diabetes. *Acta Med. Okayama* **2016**, *70*, 151–158. [[CrossRef](#)] [[PubMed](#)]
54. Anzell, A.R.; Maizy, R.; Przyklenk, K.; Sanderson, T.H. Mitochondrial quality control and disease: Insights into ischemia-reperfusion injury. *Mol. Neurobiol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
55. Nan, J.; Zhu, W.; Rahman, M.S.; Liu, M.; Li, D.; Su, S.; Zhang, N.; Hu, X.; Yu, H.; Gupta, M.P.; et al. Molecular regulation of mitochondrial dynamics in cardiac disease. *Biochim. Biophys. Acta* **2017**, *1864*, 1260–1273. [[CrossRef](#)] [[PubMed](#)]
56. Tong, M.; Sadoshima, J. Mitochondrial autophagy in cardiomyopathy. *Curr. Opin. Genet. Dev.* **2016**, *38*, 8–15. [[CrossRef](#)] [[PubMed](#)]
57. Marin-Garcia, J.; Akhmedov, A.T. Mitochondrial dynamics and cell death in heart failure. *Heart Fail. Rev.* **2016**, *21*, 123–136. [[CrossRef](#)] [[PubMed](#)]
58. Vasquez-Trincado, C.; Garcia-Carvajal, I.; Pennanen, C.; Parra, V.; Hill, J.A.; Rothermel, B.A.; Lavandro, S. Mitochondrial dynamics, mitophagy and cardiovascular disease. *J. Physiol.* **2016**, *594*, 509–525. [[CrossRef](#)] [[PubMed](#)]
59. Chiang, S.; Kalinowski, D.S.; Jansson, P.J.; Richardson, D.R.; Huang, M.L. Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, friedreich’s ataxia. *Neurochem. Int.* **2017**. [[CrossRef](#)] [[PubMed](#)]
60. Gao, J.; Wang, L.; Liu, J.; Xie, F.; Su, B.; Wang, X. Abnormalities of mitochondrial dynamics in neurodegenerative diseases. *Antioxidants* **2017**, *6*, 25. [[CrossRef](#)] [[PubMed](#)]
61. Wu, Q.; Luo, C.L.; Tao, L.Y. Dynamin-related protein 1 (Drp1) mediating mitophagy contributes to the pathophysiology of nervous system diseases and brain injury. *Histol. Histopathol.* **2017**, *32*, 551–559. [[CrossRef](#)] [[PubMed](#)]
62. Bose, A.; Beal, M.F. Mitochondrial dysfunction in parkinson’s disease. *J. Neurochem.* **2016**, *139* (Suppl. S1), 216–231. [[CrossRef](#)] [[PubMed](#)]
63. Cai, Q.; Tammineni, P. Alterations in mitochondrial quality control in alzheimer’s disease. *Front. Cell Neurosci.* **2016**, *10*, 24. [[CrossRef](#)] [[PubMed](#)]
64. Boengler, K.; Kosiol, M.; Mayr, M.; Schulz, R.; Rohrbach, S. Mitochondria and ageing: Role in heart, skeletal muscle and adipose tissue. *J. Cachexia Sarcopenia Muscle* **2017**, *8*, 349–369. [[CrossRef](#)] [[PubMed](#)]

65. Lopez-Lluch, G. Mitochondrial activity and dynamics changes regarding metabolism in ageing and obesity. *Mech. Ageing Dev.* **2017**, *162*, 108–121. [[CrossRef](#)] [[PubMed](#)]
66. Wang, W.; Gong, G.; Wang, X.; Wei-LaPierre, L.; Cheng, H.; Dirksen, R.; Sheu, S.S. Mitochondrial flash: Integrative reactive oxygen species and pH signals in cell and organelle biology. *Antioxid. Redox Signal.* **2016**, *25*, 534–549. [[CrossRef](#)] [[PubMed](#)]
67. Bae, Y.S.; Oh, H.; Rhee, S.G.; Yoo, Y.D. Regulation of reactive oxygen species generation in cell signaling. *Mol. Cells* **2011**, *32*, 491–509. [[CrossRef](#)] [[PubMed](#)]
68. Brand, M.D. Mitochondrial generation of superoxide and hydrogen peroxide as the source of mitochondrial redox signaling. *Free Radic. Biol. Med.* **2016**, *100*, 14–31. [[CrossRef](#)] [[PubMed](#)]
69. Wong, H.S.; Dighe, P.A.; Mezera, V.; Monternier, P.A.; Brand, M.D. Production of superoxide and hydrogen peroxide from specific mitochondrial sites under different bioenergetic conditions. *J. Biol. Chem.* **2017**, *292*, 16804–16809. [[CrossRef](#)] [[PubMed](#)]
70. Zou, X.; Ratti, B.A.; O'Brien, J.G.; Lautenschlager, S.O.; Gius, D.R.; Bonini, M.G.; Zhu, Y. Manganese superoxide dismutase (SOD2): Is there a center in the universe of mitochondrial redox signaling? *J. Bioenerg. Biomembr.* **2017**, *49*, 325–333. [[CrossRef](#)] [[PubMed](#)]
71. Mondola, P.; Damiano, S.; Sasso, A.; Santillo, M. The Cu, Zn superoxide dismutase: Not only a dismutase enzyme. *Front. Physiol.* **2016**, *7*, 594. [[CrossRef](#)] [[PubMed](#)]
72. Gao, X.; Schottker, B. Reduction-oxidation pathways involved in cancer development: A systematic review of literature reviews. *Oncotarget* **2017**, *8*, 51888–51906. [[CrossRef](#)] [[PubMed](#)]
73. Scialo, F.; Fernandez-Ayala, D.J.; Sanz, A. Role of mitochondrial reverse electron transport in ROS signaling: Potential roles in health and disease. *Front. Physiol.* **2017**, *8*, 428. [[CrossRef](#)] [[PubMed](#)]
74. Kuksal, N.; Chalker, J.; Mailloux, R.J. Progress in understanding the molecular oxygen paradox—function of mitochondrial reactive oxygen species in cell signaling. *Biol. Chem.* **2017**, *398*, 1209–1227. [[CrossRef](#)] [[PubMed](#)]
75. Roy, J.; Galano, J.M.; Durand, T.; Le Guennec, J.Y.; Lee, J.C. Physiological role of reactive oxygen species as promoters of natural defenses. *FASEB J.* **2017**, *31*, 3729–3745. [[CrossRef](#)] [[PubMed](#)]
76. Sies, H.; Berndt, C.; Jones, D.P. Oxidative stress. *Annu. Rev. Biochem.* **2017**, *86*, 715–748. [[CrossRef](#)] [[PubMed](#)]
77. Sies, H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. *Redox Biol.* **2017**, *11*, 613–619. [[CrossRef](#)] [[PubMed](#)]
78. Mahaseth, T.; Kuzminov, A. Potentiation of hydrogen peroxide toxicity: From catalase inhibition to stable DNA-iron complexes. *Mutat. Res.* **2017**, *773*, 274–281. [[CrossRef](#)] [[PubMed](#)]
79. Leitao, E.F.V.; Ventura, E.; de Souza, M.A.F.; Riveros, J.M.; do Monte, S.A. Spin-forbidden branching in the mechanism of the intrinsic haber-weiss reaction. *ChemistryOpen* **2017**, *6*, 360–363. [[CrossRef](#)] [[PubMed](#)]
80. Gammella, E.; Recalcati, S.; Cairo, G. Dual role of ROS as signal and stress agents: Iron tips the balance in favor of toxic effects. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 8629024. [[CrossRef](#)] [[PubMed](#)]
81. Little, A.C.; Sulovari, A.; Danyal, K.; Heppner, D.E.; Seward, D.J.; Van der Vliet, A. Paradoxical roles of dual oxidases in cancer biology. *Free Radic. Biol. Med.* **2017**, *110*, 117–132. [[CrossRef](#)] [[PubMed](#)]
82. Zou, Z.; Chang, H.; Li, H.; Wang, S. Induction of reactive oxygen species: An emerging approach for cancer therapy. *Apoptosis* **2017**, *22*, 1321–1335. [[CrossRef](#)] [[PubMed](#)]
83. Vakifahmetoglu-Norberg, H.; Ouchida, A.T.; Norberg, E. The role of mitochondria in metabolism and cell death. *Biochem. Biophys. Res. Commun.* **2017**, *482*, 426–431. [[CrossRef](#)] [[PubMed](#)]
84. Rodic, S.; Vincent, M.D. Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype. *Int. J. Cancer* **2018**, *142*, 440–448. [[CrossRef](#)] [[PubMed](#)]
85. Idelchik, M.; Begley, U.; Begley, T.J.; Melendez, J.A. Mitochondrial ROS control of cancer. *Semin. Cancer Biol.* **2017**, *47*, 57–66. [[CrossRef](#)] [[PubMed](#)]
86. Liu, J.; Wang, Z. Increased oxidative stress as a selective anticancer therapy. *Oxid. Med. Cell. Longev.* **2015**, *2015*, 294303. [[CrossRef](#)] [[PubMed](#)]
87. Chen, H.; Chan, D.C. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. *Cell Metab.* **2017**, *26*, 39–48. [[CrossRef](#)] [[PubMed](#)]
88. Raza, M.H.; Siraj, S.; Arshad, A.; Waheed, U.; Aldakheel, F.; Alduraywish, S.; Arshad, M. ROS-modulated therapeutic approaches in cancer treatment. *J. Cancer Res. Clin. Oncol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
89. Galadari, S.; Rahman, A.; Pallichankandy, S.; Thayyullathil, F. Reactive oxygen species and cancer paradox: To promote or to suppress? *Free Radic. Biol. Med.* **2017**, *104*, 144–164. [[CrossRef](#)] [[PubMed](#)]

90. Milkovic, L.; Siems, W.; Siems, R.; Zarkovic, N. Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. *Curr. Pharm. Des.* **2014**, *20*, 6529–6542. [[CrossRef](#)] [[PubMed](#)]
91. Cabello, C.M.; Bair, W.B., 3rd; Wondrak, G.T. Experimental therapeutics: Targeting the redox achilles heel of cancer. *Curr. Opin. Investig. Drugs* **2007**, *8*, 1022–1037. [[PubMed](#)]
92. Marullo, R.; Werner, E.; Degtyareva, N.; Moore, B.; Altavilla, G.; Ramalingam, S.S.; Doetsch, P.W. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. *PLoS ONE* **2013**, *8*, e81162. [[CrossRef](#)] [[PubMed](#)]
93. Mut-Salud, N.; Alvarez, P.J.; Garrido, J.M.; Carrasco, E.; Aranega, A.; Rodriguez-Serrano, F. Antioxidant intake and antitumor therapy: Toward nutritional recommendations for optimal results. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 6719534. [[CrossRef](#)] [[PubMed](#)]
94. Abo-Neima, S.E. Treatment of cancer by low intensity laser radiation therapy. *Prog. Biophys. Mol. Biol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
95. Deng, K.; Li, C.; Huang, S.; Xing, B.; Jin, D.; Zeng, Q.; Hou, Z.; Lin, J. Recent progress in near infrared light triggered photodynamic therapy. *Small* **2017**, *13*. [[CrossRef](#)] [[PubMed](#)]
96. Luo, H.; Chiang, H.H.; Louw, M.; Susanto, A.; Chen, D. Nutrient sensing and the oxidative stress response. *Trends Endocrinol. Metab.* **2017**, *28*, 449–460. [[CrossRef](#)] [[PubMed](#)]
97. Wang, C.H.; Wu, S.B.; Wu, Y.T.; Wei, Y.H. Oxidative stress response elicited by mitochondrial dysfunction: Implication in the pathophysiology of aging. *Exp. Biol. Med.* **2013**, *238*, 450–460. [[CrossRef](#)] [[PubMed](#)]
98. Yang, L.; Long, Q.; Liu, J.; Tang, H.; Li, Y.; Bao, F.; Qin, D.; Pei, D.; Liu, X. Mitochondrial fusion provides an ‘initial metabolic complementation’ controlled by mtdna. *Cell. Mol. Life Sci.* **2015**, *72*, 2585–2598. [[CrossRef](#)] [[PubMed](#)]
99. Enns, G.M.; Cowan, T.M. Glutathione as a redox biomarker in mitochondrial disease-implications for therapy. *J. Clin. Med.* **2017**, *6*, 50. [[CrossRef](#)]
100. Jiao, Y.; Wang, Y.; Guo, S.; Wang, G. Glutathione peroxidases as oncotargets. *Oncotarget* **2017**, *8*, 80093–80102. [[CrossRef](#)] [[PubMed](#)]
101. Couto, N.; Wood, J.; Barber, J. The role of glutathione reductase and related enzymes on cellular redox homeostasis network. *Free Radic. Biol. Med.* **2016**, *95*, 27–42. [[CrossRef](#)] [[PubMed](#)]
102. Shutt, T.; Geoffrion, M.; Milne, R.; McBride, H.M. The intracellular redox state is a core determinant of mitochondrial fusion. *EMBO Rep.* **2012**, *13*, 909–915. [[CrossRef](#)] [[PubMed](#)]
103. Glorieux, C.; Calderon, P.B. Catalase, a remarkable enzyme: Targeting the oldest antioxidant enzyme to find a new cancer treatment approach. *Biol. Chem.* **2017**, *398*, 1095–1108. [[CrossRef](#)] [[PubMed](#)]
104. Rhee, S.G.; Kil, I.S. Multiple functions and regulation of mammalian peroxiredoxins. *Annu. Rev. Biochem.* **2017**, *86*, 749–775. [[CrossRef](#)] [[PubMed](#)]
105. Zhang, J.; Li, X.; Han, X.; Liu, R.; Fang, J. Targeting the thioredoxin system for cancer therapy. *Trends Pharmacol. Sci.* **2017**, *38*, 794–808. [[CrossRef](#)] [[PubMed](#)]
106. Monteiro, H.P.; Ogata, F.T.; Stern, A. Thioredoxin promotes survival signaling events under nitrosative/oxidative stress associated with cancer development. *Biomed. J.* **2017**, *40*, 189–199. [[CrossRef](#)] [[PubMed](#)]
107. Cunniff, B.; Wozniak, A.N.; Sweeney, P.; DeCosta, K.; Heintz, N.H. Peroxiredoxin 3 levels regulate a mitochondrial redox setpoint in malignant mesothelioma cells. *Redox Biol.* **2014**, *3*, 79–87. [[CrossRef](#)] [[PubMed](#)]
108. Baffy, G. Mitochondrial uncoupling in cancer cells: Liabilities and opportunities. *Biochim. Biophys. Acta* **2017**, *1858*, 655–664. [[CrossRef](#)] [[PubMed](#)]
109. Jezek, J.; Dlaskova, A.; Zelenka, J.; Jaburek, M.; Jezek, P. H₂O₂-activated mitochondrial phospholipase iPLA(2)gamma prevents lipotoxic oxidative stress in synergy with UCP2, amplifies signaling via G-protein-coupled receptor GPR40, and regulates insulin secretion in pancreatic beta-cells. *Antioxid. Redox Signal.* **2015**, *23*, 958–972. [[CrossRef](#)] [[PubMed](#)]
110. Oh, S.E.; Mouradian, M.M. Cytoprotective mechanisms of DJ-1 against oxidative stress through modulating ERK1/2 and ASK1 signal transduction. *Redox Biol.* **2018**, *14*, 211–217. [[CrossRef](#)] [[PubMed](#)]
111. Almeida, L.O.; Goto, R.N.; Neto, M.P.; Sousa, L.O.; Curti, C.; Leopoldino, A.M. Set overexpression in HEK293 cells regulates mitochondrial uncoupling proteins levels within a mitochondrial fission/reduced autophagic flux scenario. *Biochem. Biophys. Res. Commun.* **2015**, *458*, 300–306. [[CrossRef](#)] [[PubMed](#)]

112. Shimizu, Y.; Lambert, J.P.; Nicholson, C.K.; Kim, J.J.; Wolfson, D.W.; Cho, H.C.; Husain, A.; Naqvi, N.; Chin, L.S.; Li, L.; et al. Dj-1 protects the heart against ischemia-reperfusion injury by regulating mitochondrial fission. *J. Mol. Cell. Cardiol.* **2016**, *97*, 56–66. [[CrossRef](#)] [[PubMed](#)]
113. Benfeitas, R.; Uhlen, M.; Nielsen, J.; Mardinoglu, A. New challenges to study heterogeneity in cancer redox metabolism. *Front. Cell Dev. Biol.* **2017**, *5*, 65. [[CrossRef](#)] [[PubMed](#)]
114. Moloney, J.N.; Cotter, T.G. ROS signalling in the biology of cancer. *Semin. Cell Dev. Biol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
115. Basak, P.; Sadhukhan, P.; Sarkar, P.; Sil, P.C. Perspectives of the NRF-2 signaling pathway in cancer progression and therapy. *Toxicol. Rep.* **2017**, *4*, 306–318. [[CrossRef](#)] [[PubMed](#)]
116. Holmstrom, K.M.; Kostov, R.V.; Dinkova-Kostova, A.T. The multifaceted role of Nrf2 in mitochondrial function. *Curr. Opin. Toxicol.* **2016**, *1*, 80–91. [[CrossRef](#)] [[PubMed](#)]
117. Krajka-Kuzniak, V.; Paluszczak, J.; Baer-Dubowska, W. The NRF2-are signaling pathway: An update on its regulation and possible role in cancer prevention and treatment. *Pharmacol. Rep.* **2017**, *69*, 393–402. [[CrossRef](#)] [[PubMed](#)]
118. Holmstrom, K.M.; Baird, L.; Zhang, Y.; Hargreaves, I.; Chalasani, A.; Land, J.M.; Stanyer, L.; Yamamoto, M.; Dinkova-Kostova, A.T.; Abramov, A.Y. Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. *Biol. Open* **2013**, *2*, 761–770. [[CrossRef](#)] [[PubMed](#)]
119. Suzuki, T.; Yamamoto, M. Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress. *J. Biol. Chem.* **2017**, *292*, 16817–16824. [[CrossRef](#)] [[PubMed](#)]
120. Jin, Y.N.; Yu, Y.V.; Gundemir, S.; Jo, C.; Cui, M.; Tieu, K.; Johnson, G.V. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. *PLoS ONE* **2013**, *8*, e57932. [[CrossRef](#)] [[PubMed](#)]
121. Negrette-Guzman, M.; Huerta-Yepe, S.; Vega, M.I.; Leon-Contreras, J.C.; Hernandez-Pando, R.; Medina-Campos, O.N.; Rodriguez, E.; Tapia, E.; Pedraza-Chaverri, J. Sulforaphane induces differential modulation of mitochondrial biogenesis and dynamics in normal cells and tumor cells. *Food Chem. Toxicol.* **2017**, *100*, 90–102. [[CrossRef](#)] [[PubMed](#)]
122. Schito, L.; Semenza, G.L. Hypoxia-inducible factors: Master regulators of cancer progression. *Trends Cancer* **2016**, *2*, 758–770. [[CrossRef](#)] [[PubMed](#)]
123. Masoud, G.N.; Li, W. Hif-1alpha pathway: Role, regulation and intervention for cancer therapy. *Acta Pharm. Sin. B* **2015**, *5*, 378–389. [[CrossRef](#)] [[PubMed](#)]
124. Nguyen, T.L.; Duran, R.V. Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism. *Int. J. Biochem. Cell Biol.* **2016**, *80*, 71–80. [[CrossRef](#)] [[PubMed](#)]
125. Ivan, M.; Kaelin, W.G., Jr. The EGLN-HIF O₂-sensing system: Multiple inputs and feedbacks. *Mol. Cell* **2017**, *66*, 772–779. [[CrossRef](#)] [[PubMed](#)]
126. Plecita-Hlavata, L.; Jezek, J.; Jezek, P. Aglycemia keeps mitochondrial oxidative phosphorylation under hypoxic conditions in HepG2 cells. *J. Bioenerg. Biomembr.* **2015**, *47*, 467–476. [[CrossRef](#)] [[PubMed](#)]
127. Hernansanz-Agustin, P.; Izquierdo-Alvarez, A.; Sanchez-Gomez, F.J.; Ramos, E.; Villa-Pina, T.; Lamas, S.; Bogdanova, A.; Martinez-Ruiz, A. Acute hypoxia produces a superoxide burst in cells. *Free Radic. Biol. Med.* **2014**, *71*, 146–156. [[CrossRef](#)] [[PubMed](#)]
128. Smith, K.A.; Waypa, G.B.; Schumacker, P.T. Redox signaling during hypoxia in mammalian cells. *Redox Biol.* **2017**, *13*, 228–234. [[CrossRef](#)] [[PubMed](#)]
129. Fernandez-Aguera, M.C.; Gao, L.; Gonzalez-Rodriguez, P.; Pintado, C.O.; Arias-Mayenco, I.; Garcia-Flores, P.; Garcia-Perganeda, A.; Pascual, A.; Ortega-Saenz, P.; Lopez-Barneo, J. Oxygen sensing by arterial chemoreceptors depends on mitochondrial complex I signaling. *Cell Metab.* **2015**, *22*, 825–837. [[CrossRef](#)] [[PubMed](#)]
130. Guzy, R.D.; Schumacker, P.T. Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. *Exp. Physiol.* **2006**, *91*, 807–819. [[CrossRef](#)] [[PubMed](#)]
131. Chandel, N.S. Mitochondrial regulation of oxygen sensing. *Adv. Exp. Med. Biol.* **2010**, *661*, 339–354. [[CrossRef](#)] [[PubMed](#)]
132. Han, X.J.; Yang, Z.J.; Jiang, L.P.; Wei, Y.F.; Liao, M.F.; Qian, Y.; Li, Y.; Huang, X.; Wang, J.B.; Xin, H.B.; et al. Mitochondrial dynamics regulates hypoxia-induced migration and antineoplastic activity of cisplatin in breast cancer cells. *Int. J. Oncol.* **2015**, *46*, 691–700. [[CrossRef](#)] [[PubMed](#)]

133. Wan, Y.Y.; Zhang, J.F.; Yang, Z.J.; Jiang, L.P.; Wei, Y.F.; Lai, Q.N.; Wang, J.B.; Xin, H.B.; Han, X.J. Involvement of Drp1 in hypoxia-induced migration of human glioblastoma u251 cells. *Oncol. Rep.* **2014**, *32*, 619–626. [[CrossRef](#)] [[PubMed](#)]
134. Salminen, A.; Kaarniranta, K.; Kauppinen, A. AMPK and HIF signaling pathways regulate both longevity and cancer growth: The good news and the bad news about survival mechanisms. *Biogerontology* **2016**, *17*, 655–680. [[CrossRef](#)] [[PubMed](#)]
135. Dier, U.; Shin, D.H.; Hemachandra, L.P.; Uusitalo, L.M.; Hempel, N. Bioenergetic analysis of ovarian cancer cell lines: Profiling of histological subtypes and identification of a mitochondria-defective cell line. *PLoS ONE* **2014**, *9*, e98479. [[CrossRef](#)] [[PubMed](#)]
136. Ryuno, H.; Naguro, I.; Kamiyama, M. ASK family and cancer. *Adv. Biol. Regul.* **2017**, *66*, 72–84. [[CrossRef](#)] [[PubMed](#)]
137. Latimer, H.R.; Veal, E.A. Peroxiredoxins in regulation of MAPK signalling pathways; sensors and barriers to signal transduction. *Mol. Cells* **2016**, *39*, 40–45. [[CrossRef](#)] [[PubMed](#)]
138. Lu, J.; Holmgren, A. Thioredoxin system in cell death progression. *Antioxid. Redox Signal.* **2012**, *17*, 1738–1747. [[CrossRef](#)] [[PubMed](#)]
139. Matsuzawa, A. Thioredoxin and redox signaling: Roles of the thioredoxin system in control of cell fate. *Arch Biochem. Biophys.* **2017**, *617*, 101–105. [[CrossRef](#)] [[PubMed](#)]
140. Kim, H.; Scimia, M.C.; Wilkinson, D.; Trelles, R.D.; Wood, M.R.; Bowtell, D.; Dillin, A.; Mercola, M.; Ronai, Z.A. Fine-tuning of Drp1/Fis1 availability by akap121/siah2 regulates mitochondrial adaptation to hypoxia. *Mol. Cell* **2011**, *44*, 532–544. [[CrossRef](#)] [[PubMed](#)]
141. Tormos, A.M.; Talens-Visconti, R.; Nebreda, A.R.; Sastre, J. P38 MAPK: A dual role in hepatocyte proliferation through reactive oxygen species. *Free Radic. Res.* **2013**, *47*, 905–916. [[CrossRef](#)] [[PubMed](#)]
142. Nakayama, K.; Qi, J.; Ronai, Z. The ubiquitin ligase siah2 and the hypoxia response. *Mol. Cancer Res.* **2009**, *7*, 443–451. [[CrossRef](#)] [[PubMed](#)]
143. Ko, S.H.; Choi, G.E.; Oh, J.Y.; Lee, H.J.; Kim, J.S.; Chae, C.W.; Choi, D.; Han, H.J. Succinate promotes stem cell migration through the gpr91-dependent regulation of Drp1-mediated mitochondrial fission. *Sci. Rep.* **2017**, *7*, 12582. [[CrossRef](#)] [[PubMed](#)]
144. Zhang, X.M.; Zhang, L.; Wang, G.; Niu, W.; He, Z.; Ding, L.; Jia, J. Suppression of mitochondrial fission in experimental cerebral ischemia: The potential neuroprotective target of p38 MAPK inhibition. *Neurochem. Int.* **2015**, *90*, 1–8. [[CrossRef](#)] [[PubMed](#)]
145. Obsil, T.; Obsilova, V. Structural aspects of protein kinase ASK1 regulation. *Adv. Biol. Regul.* **2017**, *66*, 31–36. [[CrossRef](#)] [[PubMed](#)]
146. Dhanasekaran, D.N.; Reddy, E.P. JNK signaling in apoptosis. *Oncogene* **2008**, *27*, 6245–6251. [[CrossRef](#)] [[PubMed](#)]
147. Ferro, E.; Goitre, L.; Baldini, E.; Retta, S.F.; Trabalzini, L. Ras gtpases are both regulators and effectors of redox agents. *Methods Mol. Biol.* **2014**, *1120*, 55–74. [[CrossRef](#)] [[PubMed](#)]
148. Papke, B.; Der, C.J. Drugging Ras: Know the enemy. *Science* **2017**, *355*, 1158–1163. [[CrossRef](#)] [[PubMed](#)]
149. Simanshu, D.K.; Nissley, D.V.; McCormick, F. Ras proteins and their regulators in human disease. *Cell* **2017**, *170*, 17–33. [[CrossRef](#)] [[PubMed](#)]
150. Schopel, M.; Potheraveedu, V.N.; Al-Harthy, T.; Abdel-Jalil, R.; Heumann, R.; Stoll, R. The small gtpases ras and rheb studied by multidimensional nmr spectroscopy: Structure and function. *Biol. Chem.* **2017**, *398*, 577–588. [[CrossRef](#)] [[PubMed](#)]
151. Tanimura, S.; Takeda, K. ERK signalling as a regulator of cell motility. *J. Biochem.* **2017**, *162*, 145–154. [[CrossRef](#)] [[PubMed](#)]
152. Mitchell, L.; Hobbs, G.A.; Aghajanian, A.; Campbell, S.L. Redox regulation of Ras and Rho GTPases: Mechanism and function. *Antioxid. Redox Signal.* **2013**, *18*, 250–258. [[CrossRef](#)] [[PubMed](#)]
153. Cook, S.J.; Stuart, K.; Gilley, R.; Sale, M.J. Control of cell death and mitochondrial fission by ERK1/2 map kinase signalling. *FEBS J.* **2017**, *284*, 4177–4195. [[CrossRef](#)] [[PubMed](#)]
154. Kashatus, J.A.; Nascimento, A.; Myers, L.J.; Sher, A.; Byrne, F.L.; Hoehn, K.L.; Counter, C.M.; Kashatus, D.F. ERK2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. *Mol. Cell* **2015**, *57*, 537–551. [[CrossRef](#)] [[PubMed](#)]

155. Serasinghe, M.N.; Wieder, S.Y.; Renault, T.T.; Elkhohli, R.; Ascioffa, J.J.; Yao, J.L.; Jabado, O.; Hoehn, K.; Kageyama, Y.; Sesaki, H.; et al. Mitochondrial division is requisite to ras-induced transformation and targeted by oncogenic MAPK pathway inhibitors. *Mol. Cell* **2015**, *57*, 521–536. [[CrossRef](#)] [[PubMed](#)]
156. Taguchi, N.; Ishihara, N.; Jofuku, A.; Oka, T.; Mihara, K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. *J. Biol. Chem.* **2007**, *282*, 11521–11529. [[CrossRef](#)] [[PubMed](#)]
157. Colomer, C.; Marruecos, L.; Vert, A.; Bigas, A.; Espinosa, L. Nf-kappab members left home: Nf-kappab-independent roles in cancer. *Biomedicines* **2017**, *5*, 26. [[CrossRef](#)] [[PubMed](#)]
158. Darvishi, B.; Farahmand, L.; Eslami, S.Z.; Majidzadeh, A.K. Nf-kappab as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer. *Tumour Biol.* **2017**, *39*. [[CrossRef](#)] [[PubMed](#)]
159. Begalli, F.; Bennett, J.; Capece, D.; Verzella, D.; D'Andrea, D.; Tornatore, L.; Franzoso, G. Unlocking the nf-kappab conundrum: Embracing complexity to achieve specificity. *Biomedicines* **2017**, *5*, 50. [[CrossRef](#)]
160. Capece, D.; Verzella, D.; Tessitore, A.; Alesse, E.; Capalbo, C.; Zazzeroni, F. Cancer secretome and inflammation: The bright and the dark sides of NF-κB. *Semin. Cell. Dev. Biol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
161. Laforge, M.; Rodrigues, V.; Silvestre, R.; Gautier, C.; Weil, R.; Corti, O.; Estaquier, J. Nf-kappab pathway controls mitochondrial dynamics. *Cell Death Differ.* **2016**, *23*, 89–98. [[CrossRef](#)] [[PubMed](#)]
162. Mitchell, S.; Vargas, J.; Hoffmann, A. Signaling via the NF-κB system. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **2016**, *8*, 227–241. [[CrossRef](#)] [[PubMed](#)]
163. Buelna-Chontal, M.; Zazueta, C. Redox activation of Nrf2 & NF-κB: A double end sword? *Cell Signal.* **2013**, *25*, 2548–2557. [[CrossRef](#)] [[PubMed](#)]
164. Busquets-Cortes, C.; Capo, X.; Martorell, M.; Tur, J.A.; Sureda, A.; Pons, A. Training and acute exercise modulates mitochondrial dynamics in football players' blood mononuclear cells. *Eur. J. Appl. Physiol.* **2017**, *117*, 1977–1987. [[CrossRef](#)] [[PubMed](#)]
165. Uzhachenko, R.; Ivanov, S.V.; Yarbrough, W.G.; Shanker, A.; Medzhitov, R.; Ivanova, A.V. Fus1/Tusc2 is a novel regulator of mitochondrial calcium handling, Ca²⁺-coupled mitochondrial processes, and Ca²⁺-dependent NFAT and NF-κB pathways in CD4⁺ T cells. *Antioxid. Redox Signal.* **2014**, *20*, 1533–1547. [[CrossRef](#)] [[PubMed](#)]
166. Aravamudan, B.; Kiel, A.; Freeman, M.; Delmotte, P.; Thompson, M.; Vassallo, R.; Sieck, G.C.; Pabelick, C.M.; Prakash, Y.S. Cigarette smoke-induced mitochondrial fragmentation and dysfunction in human airway smooth muscle. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2014**, *306*, L840–L854. [[CrossRef](#)] [[PubMed](#)]
167. Cordero, M.D. *AMP-Activated Protein Kinase*; Springer: Berlin/Heidelberg, Germany; New York, NY, USA, 2016.
168. Herzig, S.; Shaw, R.J. AMPK: Guardian of metabolism and mitochondrial homeostasis. *Nat. Rev. Mol. Cell Biol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
169. Carling, D. AMPK signalling in health and disease. *Curr. Opin. Cell Biol.* **2017**, *45*, 31–37. [[CrossRef](#)] [[PubMed](#)]
170. Garcia, D.; Shaw, R.J. AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance. *Mol. Cell* **2017**, *66*, 789–800. [[CrossRef](#)] [[PubMed](#)]
171. Hardie, D.G.; Lin, S.C. AMP-activated protein kinase—Not just an energy sensor. *F1000Research* **2017**, *6*, 1724. [[CrossRef](#)] [[PubMed](#)]
172. Ross, F.A.; MacKintosh, C.; Hardie, D.G. AMP-activated protein kinase: A cellular energy sensor that comes in 12 flavours. *FEBS J.* **2016**, *283*, 2987–3001. [[CrossRef](#)] [[PubMed](#)]
173. He, X.; Li, C.; Ke, R.; Luo, L.; Huang, D. Down-regulation of adenosine monophosphate-activated protein kinase activity: A driver of cancer. *Tumour Biol.* **2017**, *39*. [[CrossRef](#)] [[PubMed](#)]
174. Jeon, S.M.; Hay, N. The double-edged sword of AMPK signaling in cancer and its therapeutic implications. *Arch. Pharm. Res.* **2015**, *38*, 346–357. [[CrossRef](#)] [[PubMed](#)]
175. Faubert, B.; Vincent, E.E.; Poffenberger, M.C.; Jones, R.G. The amp-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. *Cancer Lett.* **2015**, *356*, 165–170. [[CrossRef](#)] [[PubMed](#)]
176. Zmijewski, J.W.; Banerjee, S.; Bae, H.; Friggeri, A.; Lazarowski, E.R.; Abraham, E. Exposure to hydrogen peroxide induces oxidation and activation of amp-activated protein kinase. *J. Biol. Chem.* **2010**, *285*, 33154–33164. [[CrossRef](#)] [[PubMed](#)]

177. Rabinovitch, R.C.; Samborska, B.; Faubert, B.; Ma, E.H.; Gravel, S.P.; Andrzejewski, S.; Raissi, T.C.; Pause, A.; St-Pierre, J.; Jones, R.G. AMPK maintains cellular metabolic homeostasis through regulation of mitochondrial reactive oxygen species. *Cell Rep.* **2017**, *21*, 1–9. [[CrossRef](#)] [[PubMed](#)]
178. Han, Y.; Wang, Q.; Song, P.; Zhu, Y.; Zou, M.H. Redox regulation of the amp-activated protein kinase. *PLoS ONE* **2010**, *5*, e15420. [[CrossRef](#)] [[PubMed](#)]
179. Shao, D.; Oka, S.; Liu, T.; Zhai, P.; Ago, T.; Sciarretta, S.; Li, H.; Sadoshima, J. A redox-dependent mechanism for regulation of AMPK activation by thioredoxin1 during energy starvation. *Cell Metab.* **2014**, *19*, 232–245. [[CrossRef](#)] [[PubMed](#)]
180. Auciello, F.R.; Ross, F.A.; Ikematsu, N.; Hardie, D.G. Oxidative stress activates AMPK in cultured cells primarily by increasing cellular amp and/or adp. *FEBS Lett.* **2014**, *588*, 3361–3366. [[CrossRef](#)] [[PubMed](#)]
181. Wu, S.B.; Wu, Y.T.; Wu, T.P.; Wei, Y.H. Role of ampk-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. *Biochim. Biophys. Acta* **2014**, *1840*, 1331–1344. [[CrossRef](#)] [[PubMed](#)]
182. Cheng, J.; Zhang, T.; Ji, H.; Tao, K.; Guo, J.; Wei, W. Functional characterization of amp-activated protein kinase signaling in tumorigenesis. *Biochim. Biophys. Acta* **2016**, *1866*, 232–251. [[CrossRef](#)] [[PubMed](#)]
183. Kang, S.W.; Haydar, G.; Taniane, C.; Farrell, G.; Arias, I.M.; Lippincott-Schwartz, J.; Fu, D. AMPK activation prevents and reverses drug-induced mitochondrial and hepatocyte injury by promoting mitochondrial fusion and function. *PLoS ONE* **2016**, *11*, e0165638. [[CrossRef](#)] [[PubMed](#)]
184. Toyama, E.Q.; Herzig, S.; Courchet, J.; Lewis, T.L., Jr.; Loson, O.C.; Hellberg, K.; Young, N.P.; Chen, H.; Polleux, F.; Chan, D.C.; et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. *Science* **2016**, *351*, 275–281. [[CrossRef](#)] [[PubMed](#)]
185. Georgakopoulos, N.D.; Wells, G.; Campanella, M. The pharmacological regulation of cellular mitophagy. *Nat. Chem. Biol.* **2017**, *13*, 136–146. [[CrossRef](#)] [[PubMed](#)]
186. Senft, D.; Ronai, Z.A. Regulators of mitochondrial dynamics in cancer. *Curr. Opin. Cell Biol.* **2016**, *39*, 43–52. [[CrossRef](#)] [[PubMed](#)]
187. Escobar-Henriques, M.; Anton, F. Mechanistic perspective of mitochondrial fusion: Tubulation vs. Fragmentation. *Biochim. Biophys. Acta* **2013**, *1833*, 162–175. [[CrossRef](#)] [[PubMed](#)]
188. Xie, Q.; Wu, Q.; Horbinski, C.M.; Flavahan, W.A.; Yang, K.; Zhou, W.; Dombrowski, S.M.; Huang, Z.; Fang, X.; Shi, Y.; et al. Mitochondrial control by Drp1 in brain tumor initiating cells. *Nat. Neurosci.* **2015**, *18*, 501–510. [[CrossRef](#)] [[PubMed](#)]
189. Von Eyss, B.; Jaenicke, L.A.; Kortlever, R.M.; Royla, N.; Wiese, K.E.; Letschert, S.; McDuffus, L.A.; Sauer, M.; Rosenwald, A.; Evan, G.I.; et al. A MYC-driven change in mitochondrial dynamics limits YAP/TAZ function in mammary epithelial cells and breast cancer. *Cancer Cell* **2015**, *28*, 743–757. [[CrossRef](#)] [[PubMed](#)]
190. Panciera, T.; Azzolin, L.; Cordenonsi, M.; Piccolo, S. Mechanobiology of YAP and TAZ in physiology and disease. *Nat. Rev. Mol. Cell Biol.* **2017**, *18*, 758–770. [[CrossRef](#)] [[PubMed](#)]
191. Kim, M.H.; Kim, J. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. *Cell. Mol. Life Sci.* **2017**, *74*, 1457–1474. [[CrossRef](#)] [[PubMed](#)]
192. Donner, A.J.; Szostek, S.; Hoover, J.M.; Espinosa, J.M. CDK8 is a stimulus-specific positive coregulator of p53 target genes. *Mol. Cell* **2007**, *27*, 121–133. [[CrossRef](#)] [[PubMed](#)]
193. Khakhina, S.; Cooper, K.F.; Strich, R. Med13p prevents mitochondrial fission and programmed cell death in yeast through nuclear retention of cyclin C. *Mol. Biol. Cell* **2014**, *25*, 2807–2816. [[CrossRef](#)] [[PubMed](#)]
194. Stieg, D.C.; Willis, S.D.; Ganesan, V.; Ong, K.L.; Scurzo, J.; Song, M.; Grose, J.; Strich, R.; Cooper, K.F. A complex molecular switch directs stress-induced cyclin C nuclear release through SCF (Grr1) mediated degradation of Med13. *Mol. Biol. Cell* **2017**. [[CrossRef](#)] [[PubMed](#)]
195. Li, N.; Fassl, A.; Chick, J.; Inuzuka, H.; Li, X.; Mansour, M.R.; Liu, L.; Wang, H.; King, B.; Shaik, S.; et al. Cyclin C is a haploinsufficient tumour suppressor. *Nat. Cell Biol.* **2014**, *16*, 1080–1091. [[CrossRef](#)] [[PubMed](#)]
196. Ohata, N.; Ito, S.; Yoshida, A.; Kunisada, T.; Numoto, K.; Jitsumori, Y.; Kanzaki, H.; Ozaki, T.; Shimizu, K.; Ouchida, M. Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma: Involvement of cyclin C in osteosarcoma. *Int. J. Mol. Med.* **2006**, *18*, 1153–1158. [[CrossRef](#)] [[PubMed](#)]
197. Wreesmann, V.B.; Ghossein, R.A.; Patel, S.G.; Harris, C.P.; Schnaser, E.A.; Shaha, A.R.; Tuttle, R.M.; Shah, J.P.; Rao, P.H.; Singh, B. Genome-wide appraisal of thyroid cancer progression. *Am. J. Pathol.* **2002**, *161*, 1549–1556. [[CrossRef](#)]

198. Hafsi, H.; Hainaut, P. Redox control and interplay between p53 isoforms: Roles in the regulation of basal p53 levels, cell fate, and senescence. *Antioxid. Redox Signal.* **2011**, *15*, 1655–1667. [[CrossRef](#)] [[PubMed](#)]
199. Yao, S.; Fan, L.Y.; Lam, E.W. The FOXO3-FOXO1 axis: A key cancer drug target and a modulator of cancer drug resistance. *Semin. Cancer Biol.* **2017**. [[CrossRef](#)] [[PubMed](#)]
200. Klotz, L.O.; Sanchez-Ramos, C.; Prieto-Arroyo, I.; Urbanek, P.; Steinbrenner, H.; Monsalve, M. Redox regulation of foxo transcription factors. *Redox Biol.* **2015**, *6*, 51–72. [[CrossRef](#)] [[PubMed](#)]
201. Caliceti, C.; Nigro, P.; Rizzo, P.; Ferrari, R. ROS, Notch, and Wnt signaling pathways: Crosstalk between three major regulators of cardiovascular biology. *BioMed Res. Int.* **2014**, *2014*, 318714. [[CrossRef](#)] [[PubMed](#)]
202. Verrastro, I.; Tveen-Jensen, K.; Woscholski, R.; Spickett, C.M.; Pitt, A.R. Reversible oxidation of phosphatase and tensin homolog (PTEN) alters its interactions with signaling and regulatory proteins. *Free Radic. Biol. Med.* **2016**, *90*, 24–34. [[CrossRef](#)] [[PubMed](#)]
203. Laev, S.S.; Salakhutdinov, N.F.; Lavrik, O.I. Inhibitors of nuclease and redox activity of apurinic/aprimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1). *Bioorg. Med. Chem.* **2017**, *25*, 2531–2544. [[CrossRef](#)] [[PubMed](#)]
204. Tang, S.; Hou, Y.; Zhang, H.; Tu, G.; Yang, L.; Sun, Y.; Lang, L.; Tang, X.; Du, Y.E.; Zhou, M.; et al. Oxidized ATM promotes abnormal proliferation of breast CAFs through maintaining intracellular redox homeostasis and activating the PI3K-AKT, MEK-ERK, and wnt-beta-catenin signaling pathways. *Cell Cycle* **2015**, *14*, 1908–1924. [[CrossRef](#)] [[PubMed](#)]
205. Espinosa-Diez, C.; Miguel, V.; Mennerich, D.; Kietzmann, T.; Sanchez-Perez, P.; Cadenas, S.; Lamas, S. Antioxidant responses and cellular adjustments to oxidative stress. *Redox Biol.* **2015**, *6*, 183–197. [[CrossRef](#)] [[PubMed](#)]
206. Marinho, H.S.; Real, C.; Cyrne, L.; Soares, H.; Antunes, F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. *Redox Biol.* **2014**, *2*, 535–562. [[CrossRef](#)] [[PubMed](#)]
207. Kim, B.; Song, Y.S. Mitochondrial dynamics altered by oxidative stress in cancer. *Free Radic. Res.* **2016**, *50*, 1065–1070. [[CrossRef](#)] [[PubMed](#)]
208. Huang, Q.; Zhan, L.; Cao, H.; Li, J.; Lyu, Y.; Guo, X.; Zhang, J.; Ji, L.; Ren, T.; An, J.; et al. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. *Autophagy* **2016**, *12*, 999–1014. [[CrossRef](#)] [[PubMed](#)]
209. Guido, C.; Whitaker-Menezes, D.; Lin, Z.; Pestell, R.G.; Howell, A.; Zimmers, T.A.; Casimiro, M.C.; Aquila, S.; Ando, S.; Martinez-Outschoorn, U.E.; et al. Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. *Oncotarget* **2012**, *3*, 798–810. [[CrossRef](#)] [[PubMed](#)]
210. Jung, J.U.; Ravi, S.; Lee, D.W.; McFadden, K.; Kamradt, M.L.; Toussaint, L.G.; Sitcheran, R. NIK/MAP3k14 regulates mitochondrial dynamics and trafficking to promote cell invasion. *Curr. Biol.* **2016**, *26*, 3288–3302. [[CrossRef](#)] [[PubMed](#)]
211. Prieto, J.; Torres, J. Mitochondrial dynamics: In cell reprogramming as it is in cancer. *Stem Cells Int.* **2017**, *2017*, 8073721. [[CrossRef](#)] [[PubMed](#)]
212. Son, M.J.; Kwon, Y.; Son, M.Y.; Seol, B.; Choi, H.S.; Ryu, S.W.; Choi, C.; Cho, Y.S. Mitofusins deficiency elicits mitochondrial metabolic reprogramming to pluripotency. *Cell Death Differ.* **2015**, *22*, 1957–1969. [[CrossRef](#)] [[PubMed](#)]
213. Khacho, M.; Clark, A.; Svoboda, D.S.; Azzi, J.; MacLaurin, J.G.; Meghaizel, C.; Sesaki, H.; Lagace, D.C.; Germain, M.; Harper, M.E.; et al. Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. *Cell Stem Cell* **2016**, *19*, 232–247. [[CrossRef](#)] [[PubMed](#)]
214. Yu, T.; Sheu, S.S.; Robotham, J.L.; Yoon, Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. *Cardiovasc. Res.* **2008**, *79*, 341–351. [[CrossRef](#)] [[PubMed](#)]
215. Sedlic, F.; Muravyeva, M.Y.; Sepac, A.; Sedlic, M.; Williams, A.M.; Yang, M.; Bai, X.; Bosnjak, Z.J. Targeted modification of mitochondrial ros production converts high glucose-induced cytotoxicity to cytoprotection: Effects on anesthetic preconditioning. *J. Cell. Physiol.* **2017**, *232*, 216–224. [[CrossRef](#)] [[PubMed](#)]
216. Zhang, L.; Ji, L.; Tang, X.; Chen, X.; Li, Z.; Mi, X.; Yang, L. Inhibition to Drp1 translocation can mitigate p38 MAPK-signaling pathway activation in gmc induced by hyperglycemia. *Ren. Fail.* **2015**, *37*, 903–910. [[CrossRef](#)] [[PubMed](#)]

217. Kumar, S.; Pan, C.C.; Shah, N.; Wheeler, S.E.; Hoyt, K.R.; Hempel, N.; Mythreye, K.; Lee, N.Y. Activation of Mitofusin2 by Smad2-RIN1 complex during mitochondrial fusion. *Mol. Cell* **2016**, *62*, 520–531. [[CrossRef](#)] [[PubMed](#)]
218. Zhang, L.; Gan, X.; He, Y.; Zhu, Z.; Zhu, J.; Yu, H. Drp1-dependent mitochondrial fission mediates osteogenic dysfunction in inflammation through elevated production of reactive oxygen species. *PLoS ONE* **2017**, *12*, e0175262. [[CrossRef](#)] [[PubMed](#)]
219. Roth, D.; Krammer, P.H.; Gulow, K. Dynamin related protein 1-dependent mitochondrial fission regulates oxidative signalling in t cells. *FEBS Lett.* **2014**, *588*, 1749–1754. [[CrossRef](#)] [[PubMed](#)]
220. Park, J.; Min, J.S.; Chae, U.; Lee, J.Y.; Song, K.S.; Lee, H.S.; Lee, H.J.; Lee, S.R.; Lee, D.S. Anti-inflammatory effect of oleuropein on microglia through regulation of Drp1-dependent mitochondrial fission. *J. Neuroimmunol.* **2017**, *306*, 46–52. [[CrossRef](#)] [[PubMed](#)]
221. Alam, M.M.; Sohoni, S.; Kalainayakan, S.P.; Garrossian, M.; Zhang, L. Cyclopamine tartrate, an inhibitor of hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells. *BMC Cancer* **2016**, *16*, 150. [[CrossRef](#)] [[PubMed](#)]
222. Shen, K.; Lu, F.; Xie, J.; Wu, M.; Cai, B.; Liu, Y.; Zhang, H.; Tan, H.; Pan, Y.; Xu, H. Cambogin exerts anti-proliferative and pro-apoptotic effects on breast adenocarcinoma through the induction of nadph oxidase 1 and the alteration of mitochondrial morphology and dynamics. *Oncotarget* **2016**, *7*, 50596–50611. [[CrossRef](#)] [[PubMed](#)]
223. Guo, C.; Wang, J.; Jing, L.; Ma, R.; Liu, X.; Gao, L.; Cao, L.; Duan, J.; Zhou, X.; Li, Y.; et al. Mitochondrial dysfunction, perturbations of mitochondrial dynamics and biogenesis involved in endothelial injury induced by silica nanoparticles. *Environ. Pollut.* **2017**. [[CrossRef](#)] [[PubMed](#)]
224. Zhang, B.; Davidson, M.M.; Zhou, H.; Wang, C.; Walker, W.F.; Hei, T.K. Cytoplasmic irradiation results in mitochondrial dysfunction and Drp1-dependent mitochondrial fission. *Cancer Res.* **2013**, *73*, 6700–6710. [[CrossRef](#)] [[PubMed](#)]
225. Keck, F.; Brooks-Faulconer, T.; Lark, T.; Ravishankar, P.; Bailey, C.; Salvador-Morales, C.; Narayanan, A. Altered mitochondrial dynamics as a consequence of venezuelan equine encephalitis virus infection. *Virulence* **2017**, 1–18. [[CrossRef](#)] [[PubMed](#)]
226. Michaeloudes, C.; Bhavsar, P.K.; Mumby, S.; Chung, K.F.; Adcock, I.M. Dealing with stress: Defective metabolic adaptation in chronic obstructive pulmonary disease pathogenesis. *Ann. Am. Thorac. Soc.* **2017**, *14*, S374–S382. [[CrossRef](#)] [[PubMed](#)]
227. Galloway, C.A.; Yoon, Y. Perspectives on: SGP symposium on mitochondrial physiology and medicine: What comes first, misshape or dysfunction? The view from metabolic excess. *J. Gen. Physiol.* **2012**, *139*, 455–463. [[CrossRef](#)] [[PubMed](#)]
228. Rosdah, A.A.; Holien, J.H.; Delbridge, L.M.; Dusting, G.J.; Lim, S.Y. Mitochondrial fission—A drug target for cytoprotection or cytodestruction? *Pharmacol. Res. Perspect.* **2016**, *4*, e00235. [[CrossRef](#)] [[PubMed](#)]

